US20060178589A1 - Accelerometer-based monitoring of the frequency dynamics of the isovolumic contraction phase and pathologic cardiac vibrations - Google Patents
Accelerometer-based monitoring of the frequency dynamics of the isovolumic contraction phase and pathologic cardiac vibrations Download PDFInfo
- Publication number
- US20060178589A1 US20060178589A1 US11/347,623 US34762306A US2006178589A1 US 20060178589 A1 US20060178589 A1 US 20060178589A1 US 34762306 A US34762306 A US 34762306A US 2006178589 A1 US2006178589 A1 US 2006178589A1
- Authority
- US
- United States
- Prior art keywords
- heart
- frequency
- acceleration sensor
- component
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/352—Detecting R peaks, e.g. for synchronising diagnostic apparatus; Estimating R-R interval
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B7/00—Instruments for auscultation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3627—Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0219—Inertial sensors, e.g. accelerometers, gyroscopes, tilt switches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/028—Microscale sensors, e.g. electromechanical sensors [MEMS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
- A61N1/36542—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by body motion, e.g. acceleration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36585—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by two or more physical parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
- A61N2001/0585—Coronary sinus electrodes
Definitions
- acceleration sensors to monitor LV function (including the degree of mitral regurgitation) and to optimize cardiac resynchronization therapy (CRT) or cardiac contractility modulation therapy (CCM) was disclosed.
- CTR cardiac resynchronization therapy
- CCM cardiac contractility modulation therapy
- acceleration sensors both wireless and conductively coupled, are integrated into disposable and implantable devices to monitor therapy for cardiomyopathy.
- sensors are integrated into a system for identifying target left ventricular (LV) pacing regions for CRT.
- the accelerometers are used to measure both vibration and displacement motion of the LV veins.
- the desired motion signal is acquired at the appropriate frequency.
- displacement is measured at frequencies less that about 20 Hz
- isovolumic contraction/relaxation vibrational motion is measured at frequencies of 20 Hz to 150 Hz
- vibrational motion related to mitral regurgitation is measured at frequencies greater than about 150 Hz.
- Various indices of LV function may be monitored including amplitudes and slopes of displacement motion, time intervals of vibrational motion, and changes in the time interval and frequency of mitral regurgitation signal.
- Acceleration sensors have been previously disclosed for measuring the amplitude of acceleration signals during isovolumic contraction.
- Using a uniaxial accelerometer integrated into a right ventricular (RV) pacing lead work done by Plicchi (“An implantable intracardiac accelerometer for monitoring myocardial contractility”, PACE 1996, 19:2066-2071) and others indicates that measurement of the peak amplitude of acceleration signals during the ICP correlates ventricular contractility and the rate of rise of ventricular pressure.
- Prior patent publications also disclose the measurement of peak amplitude acceleration signals to characterize contractility.
- Chinchoy [US 2004/0172079 A1 and US 2004/0172078 A1] discloses the measurement of peak amplitude of the acceleration signal during the ICP from the LV epicardium to optimize the atrioventricular (“AV”) delay and interventricular (“VV”) timing interval of a CRT device and to monitor long-term LV function. Yu and others disclose the measurement of the phase shift in the peak amplitude of acceleration signals derived from the LV and RV to optimize AV and VV interval timing of a CRT device.
- AV atrioventricular
- VV interventricular
- One variable is the influence of the acceleration signal related to the gravitational field of the earth. This acceleration signal will change with the angle of tilt of the sensor relative to the gravitational acceleration vector. Thus, depending on the orientation of the sensor in the heart, the acceleration signal due to earth's gravity may increase or decrease the peak amplitude.
- Another factor which may affect the peak amplitude is the relative motion of the lead or catheter type device to which the acceleration sensor is affixed.
- Relative motion of the acceleration sensor device in the direction of acceleration may increase the signal amplitude and, if counter to the direction of myocardial acceleration, may reduce the peak amplitude. Further, if the axis of the acceleration sensor is not parallel to the axis of motion, the amplitude of the signal will also be reduced. Lastly, the motion of the heart due to respiration may affect the accuracy of the peak amplitude.
- Monitoring changes in the frequency of the vibrational component of the ICP may be more practical and accurate than measuring amplitude changes for assessing cardiac function. Similarly, monitoring the time interval of this phase may prove more practical and accurate. Such an approach would reduce the sensitivity of the acceleration signal measurement and the interpretation of this measurement to the effects of gravity, sensor axis orientation, relative motion of the sensing device to which the sensor is affixed, and translational motion of the heart.
- systems characterize cardiac function using an acceleration sensor to acquire and analyze the frequency dynamics associated with the isovolumic contraction phase (“ICP”).
- ICP isovolumic contraction phase
- This information can be used to characterize heart function; optimize therapy for cardiomyopathy, including CRT therapy (including pacing intervals and required pharmacologic therapy); and to optimize CCM therapy.
- this information can be used to identify target pacing regions for CRT lead placement.
- analyzing the frequency dynamics can be used to characterize pathologic heart vibrational motion, such as mitral regurgitation and the third or fourth heart sound, and the response of this motion to therapy for cardiomyopathy.
- the system uses an acceleration sensor to characterize the frequency dynamics of the isovolumic contraction phase as it relates to contractility and ventricular function.
- the system measures pathologic heart vibrations such as mitral regurgitation and the third/fourth heart sounds and the effect of therapy on these signals.
- the sensor is placed into the ventricular chambers, onto the ventricular epicardium (e.g. LV), into the ventricular veins (e.g. the coronary sinus, great cardiac veins, or tributaries of this vein), or into the esophagus along the posterior side of the heart.
- the sensor can be integrated into an LV lead for CRT or CCM therapy for monitoring LV function.
- the sensor may also be incorporated into a catheter system for identifying target CRT pacing regions.
- the sensor may also be wireless and integrate into an implantable device (e.g. a stent) for long term monitoring of cardiac function.
- FIG. 1 shows a graph depicting various parameters of the cardiac pumping and ECG cycle.
- FIG. 2 shows a graph depicting the correlation of peak frequency during the isovolumic contraction phase and the change in pressure rise in the left ventricle (dP/dt).
- FIG. 3 shows vibrational acceleration signals from the epicardial surface of the left ventricle during isovolumic contraction, as measured with an accelerometer.
- FIG. 4 (A)-(E) shows a roving pacing guide wire device and acceleration-sensing catheter system for target pacing region identification and for characterizing the changes in LV function due to pacing.
- FIG. 5 shows improved myocardial performance post-stimulation as determined by an increase in the peak frequency of the isovolumic contraction phase and a shortening of the time interval of the isovolumic contraction phase.
- FIG. 6 shows shows myocardial motion mapping, display output, and target pacing identification.
- FIG. 7 shows a subpectoral or subcutaneous implantable acceleration sensor with a wireless communications capability for monitoring S1, S2, S3, and S4 and murmur-related heart sounds.
- FIG. 8 shows a graph indicating how the proper placement of an LV lead can be predicted using methods and devices according to embodiments of the invention.
- FIG. 1 A graph of the cardiac filling and pumping cycle and valvular events is shown in FIG. 1 .
- the cardiac LV pumping cycle (LV cycle) is divided into two periods: diastole and systole. Diastole is the filling period and systole is the ejection period. Five different phases of the LV cycle can be identified within the systolic and diastolic periods: isovolumic contraction 56 , ejection 58 , isovolumic relaxation 62 , early diastolic filling (rapid filling) 64 , and late diastolic filling (atrial contraction) 66 .
- Mitral valve closure 68 occurs during isovolumic contraction and aortic valve closure 72 (“AVC”) occurs during isovolumic relaxation.
- AVC aortic valve closure 72
- Also shown in the figures are the left ventricular pressure LV Press 74 , a regular electrocardiogram ECG 76 , the left ventricular end-diastolic volume LVEDV 78 , the left ventricular end-systolic volume LVESV 82 , a graph depicting heart sounds 84 , the left atrial pressure LA Press 86 , the aortic pressure 88 , a-wave 92 , c-wave 94 , and v-wave 96 .
- the ventricles During the isovolumic contraction phase, the ventricles begin to contract but there is no ejection of blood into the aorta. As the myocardial cells contract, they generate a force that results in the development of wall tension in the ventricles. This contraction causes vibrational motion that is related to cardiac and ventricular resonance. This vibrational motion in its audible form is thought to be the cause the first heart sound and is associated with mitral valve closure. The vibrations may be related to abrupt changes in acceleration and direction of flow of the blood in the ventricular chamber.
- the isovolumic contraction starts within about 10-20 ms of ventricular depolarization (i.e., the R wave on the ECG), and lasts from about 30 milliseconds to 75 milliseconds depending on the heart rate and contractility of the ventricles.
- the time interval of the isovolumic contraction phase is prolonged.
- the frequency of the vibration motion that occurs during isovolumic contraction changes with the development of myocardial tension.
- Time-frequency transform analyses of this motion indicates that in the normal heart the frequency rises from about 20 Hz to about 150 Hz in the first 20-50 ms of the isovolumic contraction period. There are approximately 5-8 cycles that occur in this time period.
- the starting frequency of the ICP vibration motion signal, the peak frequency, and the time interval of change in frequency may be affected by the mechanical and contractile properties of the ventricles. Peak frequency of this vibrational motion during ICP is probably related to the tension that develops in the ventricles and hence may be related to the contractility of the myocardium.
- FIG. 2 which shows the correlation of peak frequency during the isovolumic contraction phase and the change in pressure rise in the LV in dP/dt, a correlation between dP/dt (a surrogate for myocardial contractility) and the peak frequency during the ICP exists.
- the time interval over which this frequency rises may also be a measure of contractile function.
- the starting frequency during this phase may be related to the baseline ventricular wall tension.
- monitoring changes in the frequency dynamics of the isovolumic contraction phase can give insights into the cardiac and LV function in cardiomyopathy patients.
- This frequency information may also be used to monitor the effects of therapy, such as CRT, and to identify target pacing regions in CRT.
- monitoring changes in the time interval of the ICP can be indicative of cardiac function and the response to therapy. Because the frequency and time interval can be measured without having an accurate measure of amplitude, this approach may be preferred.
- vibrations from pathologic heart conditions may also be indicative of cardiac function and response to therapy.
- the frequency of the mitral regurgitation signal in cardiomyopathy is related to the degree of LV dilation and the back flow of blood through the mitral valve. Therapies that reduce dilation and or back flow, e.g., CRT or percutaneous annuloplasty, show a favorable response in the frequency and frequency dynamics of this vibration motion.
- the third or fourth heart sounds are also a vibrational motion that may be present in cardiomyopathy. Changes in the presence and frequency of these signal may be indicative of cardiac function and response to cardiomyopathy therapy.
- the frequency dynamics of the S4 correlates with ventricular mass which can be indicative of worsening (increased mass) or improving (reduced mass) heart failure.
- the frequency of the S1 may also correlate with LV stiffness.
- Acceleration sensors are well suited for measuring ICP vibration motion and pathologic cardiac vibrational motion.
- the sensor is preferably based on micro electromechanical (MEMs) principles, which allows for miniaturization and low power consumption.
- MEMs-based accelerometers are known to those of ordinary skill in the art and may be used in this system.
- MEMs-based accelerometers are typically fabricated from silicon or semiconductor substrates.
- the sensor may be fabricated from a radiation-resistant semiconductor as the sensor will be implanted in many cases under fluoroscopic guidance.
- the general design of the accelerometer measures capacitance changes due to the movement of a proof mass beam with a side arm interdigitated between two capacitor plates.
- MEMs-based acceleration sensors as described above can measure milli Gs (1 G equals 9.8 meters/sec 2 ) which is suitable for myocardial acceleration measurements which may occur between 50 and 2000 milli Gs or higher. While a capacitive sensor may be used in this embodiment, other acceleration sensor designs could be utilized and are known to those skilled in the art. For example, a thermal acceleration sensor could also be utilized in which the proof mass is a gas.
- a pressure sensor can sense vibrational motion and may also be used to indirectly monitor the frequency dynamics of the ICP.
- a more accurate measurement of peak amplitude can be measured by calculating the composite acceleration vector of each axis (x, y, and z). This can account for the gravitational acceleration and its effects on sensor tilting.
- the composite vector can be calculated by taking the square root of the x-axis measurement squared, plus the y-axis measurement squared, plus the z-axis measurement squared.
- This peak amplitude calculation can be applied to both the vibrational motion and the displacement motion. This may be particularly accurate during the implantation of an LV lead for CRT therapy when the patient is lying still on a procedure table.
- the sensor measures the peak in the LV veins or coronary sinus.
- Vibrational motion related to ICP may be sensed in a frequency range greater than 20 Hz and up to 200 Hz.
- the sensors may be tuned to sense the desired range.
- band pass filters or digital signal processing could eliminate or reduce frequency bands that are lower or higher.
- Sensors can be mounted on devices that access the heart or are disposed near the heart (e.g., via an esophageal probe) to optimally detect the desired ICP.
- a uniaxial sensor is oriented such that the axis of acceleration is parallel to the radial plane of the heart, i.e., toward the center of the ventricular chamber.
- two uniaxial sensors could be oriented longitudinally, e.g., anatomically base to apex, and radially, or three uniaxial sensors, oriented longitudinally, radially, and laterally, may be used.
- a single triaxial sensor could measure all these components.
- two dual-axis sensors are oriented perpendicularly to each other in the catheter or LV lead device. This provides three axes in the appropriate planes.
- the acceleration sensor is coupled to a signal processing and powering module.
- a battery may be used to power the sensor but other sources may also be utilized.
- Acquisition of the signal may be triggered by a ventricular depolarization signal from a cardiac electrogram.
- the R-wave from a surface cardiac electrogram (ECG) may serve as a trigger.
- the vibrational acceleration signal may then be acquired for about 100 ms.
- a shorter time interval for sampling could also be used (e.g., 50 ms) to focus in on the initial frequency associated with a rise in ventricular wall tension.
- a longer sampling interval may be used to acquire the mitral valve regurgitation and third/fourth heart sound signals.
- the R-wave or another signal of ventricular depolarization can also be used to provide a zero point for the acquisition of acceleration signals, and will also factor in the effects of gravity and tilt of the sensor.
- the accelerations signal measured around the time of the R-wave signal can be used as an off-set correction for subsequently acquired signals.
- the signal may be first amplified by an isolation amplifier that provides an isolation barrier to reduce the potential for electric shock hazard.
- the signal may be then band-pass-filtered to remove low frequency (e.g. ⁇ 20 Hz) and high frequency (e.g. >300 Hz) signals.
- the signal may then be subject to processing, both digital and analog, to characterize and identify the frequency changes of the ICP.
- Representative analog processing may be used to measure the spacing between signal crossing above a certain threshold (e.g. +/ ⁇ 10-50 milli Gs).
- the time interval between the first two crossings may be indicative of the base line frequency.
- the shortest time interval between crossings may be indicative of the highest frequency.
- Digital signal processing could include the mathematical computations such as time-frequency transforms (See, e.g.
- the output of the signal processing could be digital or analog and could be displayed on a workstation for graphical display of the ICP vibration.
- an analog output would allow the signal to be input into a multi-channel electrogram recorder.
- the workstation would typically have data storage and analysis capabilities.
- a single number such as the peak frequency or peak frequency divided by measured time interval, could be displayed.
- An accurate peak amplitude could be multiplied or divided by the time interval or frequency, or both multipled and divided by the time interval or frequency, to yield a value related to LV function and improved response to therapies such as cardiac resynchronization therapy. Changes in this number would be used to guide the therapy and make changes such as the position of the LV pacing lead.
- Devices and systems for incorporating acceleration sensors are described in the pending non-provisional patent application incorporated by reference above.
- the disclosed devices could be used to characterize the frequency dynamics of the ICP and pathologic LV vibration motion.
- Descriptions of exemplary devices are representative of acceleration sensing devices for the ICP and pathologic heart sounds.
- An acceleration sensor may be incorporated into a catheter for insertion into the LV veins such as the coronary sinus, great cardiac veins, or tributary vessels of these veins.
- the acceleration sensor may also be incorporated into a probe inserted into the esophagus, which lies immediately behind the posterior surface of the heart.
- the acceleration sensor may be a single dual axis sensor oriented perpendicularly to the long axis of the catheter. This orientation of the sensor allows the measurement of longitudinal and radial acceleration signals, which predominate in the heart, from the coronary sinus and great cardiac vein.
- the catheter probe may have a guidewire lumen; however this may not be required for an esophageal probe.
- the catheter or esophageal probe may monitor the frequency dynamics of the ICP and assess LV function.
- the esophageal probe could be used to monitor the ICP and third and fourth heart sounds to detect ischemia, for example during surgical procedures. For example, a decrease in amplitude of the ICP signal as measured by the esophageal probe could be indicative of ischemia. Because the esophageal probe would not move with heart contraction and the patient would be still during surgery, more accurate amplitude measures could be obtained.
- a guide catheter 102 is shown with a proximal end 104 .
- An acceleration sensing catheter 100 that may be inserted into the guide catheter 102 , is shown with a pacing guidewire port 114 and a guidewire lumen 108 .
- the guidewire lumen may have a diameter of, e.g., 0.014′′ to 0.038′′.
- the catheter 100 also has a sensor assembly 106 that may have one, two, or three acceleration sensors disposed within, the sensors being disposed perpendicularly to each other.
- the catheter 100 may have a bend near the distal end thereof, as shown in FIG. 4 (B). The bend may be from 0 degrees to 90 degrees.
- a power source such as a battery 126 , a connector for low frequency ( ⁇ 20 Hz) signals 124 , a connector for mid-frequency (20 Hz to 150 Hz) signals 122 , and a connector for high frequency (>150 Hz) signals 118 .
- a pacing guidewire 120 is shown in FIG. 4 (C) having an insulated region 128 and an uninsulated region 132 for pacing.
- a flexible conductor 134 is disposed at the proximal portion of the guidewire 120 , as well as a connector 136 to a pulse generator.
- FIG. 4 (D) shows a more detailed view of the catheter 100 , showing the guide lumen 108 and an alternate sensor assembly 112 .
- the sensor assembly 112 is perpendicular to the long axis of the catheter 100 .
- the mapping system 710 is made of an acceleration sensing catheter 700 and a pacing guidewire 684 .
- the pacing guidewire may be powered by a pulse generator 712 .
- the output of the sensors may be connected to a signal conditioning module and battery power module 714 prior to input into the electrogram recording 716 and display device 718 .
- the output of the signal conditioning module may be analog signals if the electrocardiogram display is to be used.
- the signal conditioning module may also be used to correct or zero out the effects of gravity and the related tilt signal. Output from the signal conditioning module may also be digital.
- a microprocessing chip in the conditioning module may also perform functions such as forming a composite signal from multiple orientation axes and integration.
- the catheter within the guide catheter may have a guidewire lumen through which a pacing guidewire may be used to test pace target sites. This catheter may also have a port for contrast injection and may additionally have a balloon to perform an occlusive venogram.
- a pacing guidewire would be positioned in various regions of the LV veins to elicit contractions.
- the LV response to this pacing may be measured by monitoring the frequency dynamics of the vibrational motion during ICP with the catheter.
- FIG. 5 indicates this technique.
- the figure shows improved myocardial funcation post-stimulation as determined by an increase in the peak frequency of the isovolumic contraction phase.
- the left side of FIG. 5 shows the pre-stimulation signal, and the right side shows the post-stimulation signal.
- the peak frequency increases post-stimulation from about 80 Hz to about 170 Hz (note that the peak frequency is related to the time interval of the threshold crossing).
- the isovolumic contraction phase signal was acquired by sampling over a 100 ms time period after the onset of the QRS ECG signal.
- the frequency dynamics or amplitude could be measured with the esophageal probe.
- LV regions associated with changes in the ICP frequency indicative of improved LV function would be target pacing regions. For example, an increase in the peak frequency, the rate of change of the frequency over time, a reduction in the baseline frequency, or some combination of the three may be indicative of improved LV function.
- the location of implantation and pacing of the RV lead or right atrial lead may also be optimized by test pacing and monitoring the frequency dynamics of the ICP.
- the change in the presence or frequency of the third or fourth heart sounds may also be indicative of a favorable response to pacing and hence help identify a target pacing region. Changes in the frequency and duration of vibration motion related to mitral valve regurgitation may also help guide therapy and target pacing regions. Thus a reduction in the frequency or duration of the signal may be indicative of a favorable response.
- FIG. 6 which shows myocardial motion mapping, display output, and target pacing identification through a roving pace guidewire
- changes or variables indicative of a favorable LV functional response may be sensed at the low, mid, and high frequency ranges.
- MVR refers to mitral valve regurgitation
- IVC refers to isovolumic contraction
- IVR refers to isovolumic relaxation.
- the top curve is ECG 556
- curve 558 shows the velocity or LV displacement, obtained by integrating the acceleration signal
- curve 562 shows LV function
- curve 562 shows the sounds of mitral valve regurgitation.
- the accelerometer for monitoring the frequency dynamics of heart sounds may also be integrated into a pulse generator of a CRT/defibrillator device, including leadless defibrillator devices implanted subcutaneously over the chest.
- This device would be implanted subcutaneously on the chest or abdomen and would sense the vibrational motion of the heart sounds (S1, S2, S3, S4 and valvular murmurs) to characterize the peak amplitude and frequency.
- This pulse generator could perform software algorithms to characterize the frequency dynamics of these sounds and assess LV function and pathology including contractility, mitral regurgitation, LV thickening etc.
- the start of systole as measured by the cardiac electrogram could be used to synchronize the accelerometer sensor with the onset of systole.
- the S1 vibrational motion as measured by the accelerometer would occur within a few milliseconds of the sensed electrogram.
- additional vibrational motion S2, S3, and S4 and murmurs
- Additional a time window of sensing with the acceleration sensor eg. 100 ms
- This information could be uploaded via a radiofrequency link to provide a read out to the physician for monitoring purposes.
- the RF communication device that would acquire the data from the pulse generator could reside at the patients home and be transmitted to a physician or central monitoring station via the internet or a phone line link.
- the accelerometer could be used to sense that the patient in whom the device is implanted is not moving and is in the proper orientation (eg. upright or lying flat) prior to the acquisition of the heart function data.
- a stand alone implantable accelerometer device (i.e. not incorporated into the IPG/CRT device) could also be implanted subcutaneously or subpectorally and not require an transvenous lead or extension.
- IAD implantable accelerometer device
- a subpectorally-placed IAD 208 may be disposed adjacent the pectoral muscle 210 of a patient.
- the device 208 may have an acceleration sensor 220 , an RF communications transceiver chip 214 and antenna 212 , signal processing and control circuit 218 with digital memory storage capacity 222 , and a battery 216 .
- the device 208 may be contained in a hermetically sealed titanium shell 202 .
- the device could have a curved form factor as shown in FIG. 7 (A) to lie flat along the chest.
- the antenna could be wire wound or integrated onto the communications chip.
- the sensor may be a low-power consumption 3-axis MEMs device.
- the device may sense at a frequency greater than about 20 Hz to avoid acceleration signals due to respiration or displacement motion of the heart.
- Optional electrodes 204 and 206 with accompanying circuitry may be employed to obtain a surface cardiac electrogram. As shown in FIG. 7 (A), the electrodes would reside on the side of the device that is oriented toward the heart. 3-7 years of battery life may be provided, although variations are within the scope of the invention.
- Low power RF transceiver chips (applications specific integrated circuit or ASIC), such as that produced by Zarlink Semiconductor of San Diego, Calif. (e.g., model number ZL 70100) can improve battery life and data transmission of the device.
- the device need not require leads that extend into the heart and may reside in proximity to the left ventricle after subcutaneous or subpectoral implantation.
- the device may sense and measure vibrational data related to LV function and pathology such as frequency dynamics, time intervals, and peak amplitude of the ICP, S1, S2, S3, S4, and valvular murmurs.
- the surface of the device oriented toward the heart may have electrodes for sensing the surface electrocardiogram and the onset of the QRS.
- the S1 As the vibrational signal immediately following the QRS.
- the subsequent vibrational signals could also be identified and time windows of sensing could also be incorporated to focus on the desired heart sound/vibrational motion.
- a narrow window of sensing that ascertains only the S1 vibrational signal may be preferred to avoid signal distortion or noise caused by movement of the heart against the chest during displacement or ejection.
- the S1 may be sensed and averaged over several to many beats.
- the vibrational motion could be sensed continuously or periodically. Periodic sensing may be used to extend battery life. The data may be collected at the same time during each day (e.g., at bedtime during quiet resting).
- the acceleration data could be stored or uploaded via an RF link in real time.
- the accelerometer could be battery-powered or inductively-powered with an RF coil.
- the data could be periodically or in real time uploaded with an RF link to a signal processing station for monitoring of the LV function such as contractility and pathology such as LV mass/thickness and valvular murmurs.
- the uploaded data could be sent via the internet to a physician or central monitoring station or both.
- the device could also interface with a cell phone type device for the same purpose of uploading data from the IAD.
- Analysis of the frequency dynamics of the ICP could also be used to optimize the pacing timing intervals for CRT (A-V and V-V).
- V-V timing could be set to 0 ms (both ventricles paced simultaneously), and the AV delay could be varied between about 100 and 140 ms.
- the AV delay that provides a the highest peak frequency (or some other measure of improved cardiac function) during ICP could be chosen.
- the A-V delay would be fixed at the previously determined optimal value and the V-V delay could be varied between ⁇ 30 ms (LV to RV; thus ⁇ 30 means the RV was paced 30 ms before the LV) to +30 ms LV to RV.
- the interval causing the highest peak frequency during ICP may be chosen.
- An automated system could run through the various pacing timing intervals and monitor the frequency dynamics of the ICP and provide optimal timing intervals.
- the acceleration sensor may also be incorporated into the lead of a CRT or CCM device.
- the sensor may monitor the frequency dynamics of the ICP to ascertain cardiac function in a manner similar to the above.
- the sensor could also be used to test different timing intervals for the atrioventricular and interventricular timing.
- the sensor may also be integrated into other implantable devices such as cardiac stents or epicardial leads to monitor cardiac function through analysis of the frequency dynamics of the ICP and pathologic heart sounds.
- FIG. 8 shows how information from the acceleration sensor can be employed to develop a predictive algorithm for determining CRT response.
- the peak amplitude and peak frequency are seen at LV site #3.
- a linear threshold relationship or other such relationship, may be employed to determine when LV lead placement is acceptable for any given patient. If the amplitude is high enough at a certain frequency, and thus is above the linear threshold, then the response may be deemed to be good and the site chosen as a location for an LV lead.
Abstract
Methods and systems are disclosed that characterize cardiac function using an acceleration sensor to acquire and analyze the frequency dynamics associated with the isovolumic contraction phase (“ICP”). This information can be used to characterize heart function; optimize therapy for cardiomyopathy, including CRT therapy (including pacing intervals and required pharmacologic therapy); and to optimize CCM therapy. In addition, this information can be used to identify target pacing regions for CRT lead placement. Further, analyzing the frequency dynamics can be used to characterize pathologic heart vibrational motion, such as mitral regurgitation and the third or fourth heart sound, and the response of this motion to therapy for cardiomyopathy.
Description
- This application claims the benefit of U.S. Provisional Application No. 60/650,532, filed Feb. 7, 2005, U.S. Provisional Application No. 60/655,038, filed Feb. 22, 2005, U.S. Provisional Application No. 60/656,307, filed Feb. 25, 2005, U.S. Provisional Application No. 60/657,766, filed Mar. 1, 2005, U.S. Provisional Application No. 60/659,658, filed Mar. 8, 2005, U.S. Provisional Application No. 60/663,788, filed Mar. 21, 2005, U.S. Provisional Application No. 60/669,324, filed Apr. 7, 2005, U.S. Provisional Application No. 60/677,569, filed May 4, 2005 and U.S. Provisional Application No. 60/680,673, filed May 13, 2005. Each of the prior U.S. Provisional Patent Applications is incorporated by reference in its entirety herein.
- This application is also related to U.S. patent application Ser. No. 11/318,325, filed Dec. 23, 2005, entitled “Devices and Methods For Accelerometer-Based Characterization of Cardiac Function and Identification of LV Target Pacing Zones,” which is incorporated by reference herein in its entirety.
- In prior provisional applications of the inventor, the use of acceleration sensors to monitor LV function (including the degree of mitral regurgitation) and to optimize cardiac resynchronization therapy (CRT) or cardiac contractility modulation therapy (CCM) was disclosed. In these applications, acceleration sensors, both wireless and conductively coupled, are integrated into disposable and implantable devices to monitor therapy for cardiomyopathy. In addition, sensors are integrated into a system for identifying target left ventricular (LV) pacing regions for CRT. The accelerometers are used to measure both vibration and displacement motion of the LV veins. The desired motion signal is acquired at the appropriate frequency. Thus, displacement is measured at frequencies less that about 20 Hz, isovolumic contraction/relaxation vibrational motion is measured at frequencies of 20 Hz to 150 Hz, and vibrational motion related to mitral regurgitation is measured at frequencies greater than about 150 Hz. Various indices of LV function may be monitored including amplitudes and slopes of displacement motion, time intervals of vibrational motion, and changes in the time interval and frequency of mitral regurgitation signal.
- Acceleration sensors have been previously disclosed for measuring the amplitude of acceleration signals during isovolumic contraction. Using a uniaxial accelerometer integrated into a right ventricular (RV) pacing lead, work done by Plicchi (“An implantable intracardiac accelerometer for monitoring myocardial contractility”, PACE 1996, 19:2066-2071) and others indicates that measurement of the peak amplitude of acceleration signals during the ICP correlates ventricular contractility and the rate of rise of ventricular pressure. Prior patent publications also disclose the measurement of peak amplitude acceleration signals to characterize contractility. For example, Chinchoy [US 2004/0172079 A1 and US 2004/0172078 A1] discloses the measurement of peak amplitude of the acceleration signal during the ICP from the LV epicardium to optimize the atrioventricular (“AV”) delay and interventricular (“VV”) timing interval of a CRT device and to monitor long-term LV function. Yu and others disclose the measurement of the phase shift in the peak amplitude of acceleration signals derived from the LV and RV to optimize AV and VV interval timing of a CRT device.
- Accurate measurement of the peak amplitude of an acceleration signal using an acceleration sensor as discussed in prior disclosures, may be problematic due to variables that can affect the signal. One variable is the influence of the acceleration signal related to the gravitational field of the earth. This acceleration signal will change with the angle of tilt of the sensor relative to the gravitational acceleration vector. Thus, depending on the orientation of the sensor in the heart, the acceleration signal due to earth's gravity may increase or decrease the peak amplitude. Another factor which may affect the peak amplitude is the relative motion of the lead or catheter type device to which the acceleration sensor is affixed. Relative motion of the acceleration sensor device (e.g., a catheter LV lead) in the direction of acceleration may increase the signal amplitude and, if counter to the direction of myocardial acceleration, may reduce the peak amplitude. Further, if the axis of the acceleration sensor is not parallel to the axis of motion, the amplitude of the signal will also be reduced. Lastly, the motion of the heart due to respiration may affect the accuracy of the peak amplitude.
- Further in the disclosures of Chinchoy and Yu [US 2003/0104596 A1], it is not clear if the sensor is measuring vibrational or displacement motion of the heart. Measurement of these different motion types requires signal acquisition in the appropriate frequency band; however, these prior disclosures do not indicate the acquired acceleration signal's frequency band. Chinchoy indicates that the isovolumic contraction phase analyzed from the acceleration signal correlates with the S1 peak of myocardial Tissue Doppler velocity curve. However, this curve is a measurement of the displacement motion of the LV and therefore does not contain the vibrational component that may be more indicative of LV function. These above disclosures do not provide for measurement of pathologic vibrational motion, such as mitral regurgitation or the third/fourth heart sounds, and monitoring changes that may be indicative of improved LV function. Lastly, the above disclosures do not disclose a system and method for identifying target LV pacing sites for CRT through appropriate analysis of the ICP.
- Monitoring changes in the frequency of the vibrational component of the ICP may be more practical and accurate than measuring amplitude changes for assessing cardiac function. Similarly, monitoring the time interval of this phase may prove more practical and accurate. Such an approach would reduce the sensitivity of the acceleration signal measurement and the interpretation of this measurement to the effects of gravity, sensor axis orientation, relative motion of the sensing device to which the sensor is affixed, and translational motion of the heart.
- In this disclosure, systems characterize cardiac function using an acceleration sensor to acquire and analyze the frequency dynamics associated with the isovolumic contraction phase (“ICP”). This information can be used to characterize heart function; optimize therapy for cardiomyopathy, including CRT therapy (including pacing intervals and required pharmacologic therapy); and to optimize CCM therapy. In addition, this information can be used to identify target pacing regions for CRT lead placement. Lastly, but not exhaustively, analyzing the frequency dynamics can be used to characterize pathologic heart vibrational motion, such as mitral regurgitation and the third or fourth heart sound, and the response of this motion to therapy for cardiomyopathy.
- The system uses an acceleration sensor to characterize the frequency dynamics of the isovolumic contraction phase as it relates to contractility and ventricular function. In addition the system measures pathologic heart vibrations such as mitral regurgitation and the third/fourth heart sounds and the effect of therapy on these signals. The sensor is placed into the ventricular chambers, onto the ventricular epicardium (e.g. LV), into the ventricular veins (e.g. the coronary sinus, great cardiac veins, or tributaries of this vein), or into the esophagus along the posterior side of the heart. The sensor can be integrated into an LV lead for CRT or CCM therapy for monitoring LV function. The sensor may also be incorporated into a catheter system for identifying target CRT pacing regions. The sensor may also be wireless and integrate into an implantable device (e.g. a stent) for long term monitoring of cardiac function.
-
FIG. 1 shows a graph depicting various parameters of the cardiac pumping and ECG cycle. -
FIG. 2 shows a graph depicting the correlation of peak frequency during the isovolumic contraction phase and the change in pressure rise in the left ventricle (dP/dt). -
FIG. 3 shows vibrational acceleration signals from the epicardial surface of the left ventricle during isovolumic contraction, as measured with an accelerometer. -
FIG. 4 (A)-(E) shows a roving pacing guide wire device and acceleration-sensing catheter system for target pacing region identification and for characterizing the changes in LV function due to pacing. -
FIG. 5 shows improved myocardial performance post-stimulation as determined by an increase in the peak frequency of the isovolumic contraction phase and a shortening of the time interval of the isovolumic contraction phase. -
FIG. 6 shows shows myocardial motion mapping, display output, and target pacing identification. -
FIG. 7 shows a subpectoral or subcutaneous implantable acceleration sensor with a wireless communications capability for monitoring S1, S2, S3, and S4 and murmur-related heart sounds. -
FIG. 8 shows a graph indicating how the proper placement of an LV lead can be predicted using methods and devices according to embodiments of the invention. - A graph of the cardiac filling and pumping cycle and valvular events is shown in
FIG. 1 . The cardiac LV pumping cycle (LV cycle) is divided into two periods: diastole and systole. Diastole is the filling period and systole is the ejection period. Five different phases of the LV cycle can be identified within the systolic and diastolic periods:isovolumic contraction 56,ejection 58,isovolumic relaxation 62, early diastolic filling (rapid filling) 64, and late diastolic filling (atrial contraction) 66. Mitral valve closure 68 (“MVC”) occurs during isovolumic contraction and aortic valve closure 72 (“AVC”) occurs during isovolumic relaxation. Also shown in the figures are the left ventricularpressure LV Press 74, aregular electrocardiogram ECG 76, the left ventricular end-diastolic volume LVEDV 78, the left ventricular end-systolic volume LVESV 82, a graph depicting heart sounds 84, the left atrial pressure LA Press 86, theaortic pressure 88, a-wave 92, c-wave 94, and v-wave 96. - During the isovolumic contraction phase, the ventricles begin to contract but there is no ejection of blood into the aorta. As the myocardial cells contract, they generate a force that results in the development of wall tension in the ventricles. This contraction causes vibrational motion that is related to cardiac and ventricular resonance. This vibrational motion in its audible form is thought to be the cause the first heart sound and is associated with mitral valve closure. The vibrations may be related to abrupt changes in acceleration and direction of flow of the blood in the ventricular chamber.
- In the normal heart, the isovolumic contraction starts within about 10-20 ms of ventricular depolarization (i.e., the R wave on the ECG), and lasts from about 30 milliseconds to 75 milliseconds depending on the heart rate and contractility of the ventricles. In the cardiomyopathic heart, the time interval of the isovolumic contraction phase is prolonged.
- The frequency of the vibration motion that occurs during isovolumic contraction changes with the development of myocardial tension. Time-frequency transform analyses of this motion indicates that in the normal heart the frequency rises from about 20 Hz to about 150 Hz in the first 20-50 ms of the isovolumic contraction period. There are approximately 5-8 cycles that occur in this time period. Referring to
FIG. 3 , vibrational acceleration signals from the epicardial surface of the LV are shown during isovolumic contraction as measured with an accelerometer. The amplitudes of these cycles ranges from about 50 to 100 milli Gs (1 G=9.8 m/sec2) up to about 1 to 3 Gs. - Analysis of the frequency dynamics of the ICP can be used to characterize cardiac function. Thus the starting frequency of the ICP vibration motion signal, the peak frequency, and the time interval of change in frequency, may be affected by the mechanical and contractile properties of the ventricles. Peak frequency of this vibrational motion during ICP is probably related to the tension that develops in the ventricles and hence may be related to the contractility of the myocardium. Referring to
FIG. 2 , which shows the correlation of peak frequency during the isovolumic contraction phase and the change in pressure rise in the LV in dP/dt, a correlation between dP/dt (a surrogate for myocardial contractility) and the peak frequency during the ICP exists. The time interval over which this frequency rises may also be a measure of contractile function. The starting frequency during this phase may be related to the baseline ventricular wall tension. - In diseased hearts, such as those with cardiomyopathy, the contractile function of the myocardium is reduced, and changes in the thickness and diameter of the LV can cause an increase in the wall tension. These changes also lead to an increase in the time interval of the isovolumic contraction phase. Therefore, monitoring changes in the frequency dynamics of the isovolumic contraction phase can give insights into the cardiac and LV function in cardiomyopathy patients. This frequency information may also be used to monitor the effects of therapy, such as CRT, and to identify target pacing regions in CRT. Similarly, monitoring changes in the time interval of the ICP can be indicative of cardiac function and the response to therapy. Because the frequency and time interval can be measured without having an accurate measure of amplitude, this approach may be preferred.
- Similarly, vibrations from pathologic heart conditions may also be indicative of cardiac function and response to therapy. The frequency of the mitral regurgitation signal in cardiomyopathy is related to the degree of LV dilation and the back flow of blood through the mitral valve. Therapies that reduce dilation and or back flow, e.g., CRT or percutaneous annuloplasty, show a favorable response in the frequency and frequency dynamics of this vibration motion. The third or fourth heart sounds are also a vibrational motion that may be present in cardiomyopathy. Changes in the presence and frequency of these signal may be indicative of cardiac function and response to cardiomyopathy therapy. For example, the frequency dynamics of the S4 correlates with ventricular mass which can be indicative of worsening (increased mass) or improving (reduced mass) heart failure. The frequency of the S1 may also correlate with LV stiffness.
- Acceleration sensors are well suited for measuring ICP vibration motion and pathologic cardiac vibrational motion. The sensor is preferably based on micro electromechanical (MEMs) principles, which allows for miniaturization and low power consumption. The design and fabrication of capacitance MEMs-based accelerometers are known to those of ordinary skill in the art and may be used in this system. MEMs-based accelerometers are typically fabricated from silicon or semiconductor substrates. The sensor may be fabricated from a radiation-resistant semiconductor as the sensor will be implanted in many cases under fluoroscopic guidance. The general design of the accelerometer measures capacitance changes due to the movement of a proof mass beam with a side arm interdigitated between two capacitor plates. As the proof mass beam and side arm move with acceleration or vibration, the capacitance changes and can be output as a measure of motion. These accelerometers are fabricated from silicon substrates which allows for single-chip fabrication of the sensor with the necessary signal processing circuitry. This single-chip design increases the device's sensitivity as extremely small changes in capacitance can be measured. MEMs-based acceleration sensors as described above can measure milli Gs (1 G equals 9.8 meters/sec2) which is suitable for myocardial acceleration measurements which may occur between 50 and 2000 milli Gs or higher. While a capacitive sensor may be used in this embodiment, other acceleration sensor designs could be utilized and are known to those skilled in the art. For example, a thermal acceleration sensor could also be utilized in which the proof mass is a gas. Also, while a multi axis (2 or 3 axes) is preferred, single axis sensors could also be used and oriented appropriately to detect different axes of motion. It should also be noted that a pressure sensor can sense vibrational motion and may also be used to indirectly monitor the frequency dynamics of the ICP.
- Preferably 3-axis sensing is utilized. A more accurate measurement of peak amplitude can be measured by calculating the composite acceleration vector of each axis (x, y, and z). This can account for the gravitational acceleration and its effects on sensor tilting. The composite vector can be calculated by taking the square root of the x-axis measurement squared, plus the y-axis measurement squared, plus the z-axis measurement squared. This peak amplitude calculation can be applied to both the vibrational motion and the displacement motion. This may be particularly accurate during the implantation of an LV lead for CRT therapy when the patient is lying still on a procedure table. Here the sensor measures the peak in the LV veins or coronary sinus.
- Vibrational motion related to ICP may be sensed in a frequency range greater than 20 Hz and up to 200 Hz. The sensors may be tuned to sense the desired range. Alternatively, band pass filters or digital signal processing could eliminate or reduce frequency bands that are lower or higher.
- Sensors can be mounted on devices that access the heart or are disposed near the heart (e.g., via an esophageal probe) to optimally detect the desired ICP. In one embodiment, a uniaxial sensor is oriented such that the axis of acceleration is parallel to the radial plane of the heart, i.e., toward the center of the ventricular chamber. Alternatively, two uniaxial sensors could be oriented longitudinally, e.g., anatomically base to apex, and radially, or three uniaxial sensors, oriented longitudinally, radially, and laterally, may be used. A single triaxial sensor could measure all these components. In another embodiment, two dual-axis sensors are oriented perpendicularly to each other in the catheter or LV lead device. This provides three axes in the appropriate planes.
- The acceleration sensor is coupled to a signal processing and powering module. A battery may be used to power the sensor but other sources may also be utilized. Acquisition of the signal may be triggered by a ventricular depolarization signal from a cardiac electrogram. For example, the R-wave from a surface cardiac electrogram (ECG) may serve as a trigger. The vibrational acceleration signal may then be acquired for about 100 ms. A shorter time interval for sampling could also be used (e.g., 50 ms) to focus in on the initial frequency associated with a rise in ventricular wall tension. A longer sampling interval may be used to acquire the mitral valve regurgitation and third/fourth heart sound signals. The R-wave or another signal of ventricular depolarization can also be used to provide a zero point for the acquisition of acceleration signals, and will also factor in the effects of gravity and tilt of the sensor. Thus, the accelerations signal measured around the time of the R-wave signal can be used as an off-set correction for subsequently acquired signals.
- The signal may be first amplified by an isolation amplifier that provides an isolation barrier to reduce the potential for electric shock hazard. The signal may be then band-pass-filtered to remove low frequency (e.g. <20 Hz) and high frequency (e.g. >300 Hz) signals. The signal may then be subject to processing, both digital and analog, to characterize and identify the frequency changes of the ICP. Representative analog processing may be used to measure the spacing between signal crossing above a certain threshold (e.g. +/−10-50 milli Gs). The time interval between the first two crossings may be indicative of the base line frequency. The shortest time interval between crossings may be indicative of the highest frequency. Digital signal processing could include the mathematical computations such as time-frequency transforms (See, e.g. “Time-frequency transforms: a new approach to first heart sound frequency dynamics”, IEEE transactions in Biomedical Engineering, vol. 39, no. 7, July 1992) with peak frequency identification. Taking the mathematical derivative of the acceleration signal, analog or digital, would identify jerk motion. Measuring the jerk signals and the time difference between these signals could similarly characterize the frequency signal.
- The output of the signal processing could be digital or analog and could be displayed on a workstation for graphical display of the ICP vibration. For example, an analog output would allow the signal to be input into a multi-channel electrogram recorder. The workstation would typically have data storage and analysis capabilities. Alternatively a single number, such as the peak frequency or peak frequency divided by measured time interval, could be displayed. An accurate peak amplitude could be multiplied or divided by the time interval or frequency, or both multipled and divided by the time interval or frequency, to yield a value related to LV function and improved response to therapies such as cardiac resynchronization therapy. Changes in this number would be used to guide the therapy and make changes such as the position of the LV pacing lead.
- Devices and systems for incorporating acceleration sensors are described in the pending non-provisional patent application incorporated by reference above. The disclosed devices could be used to characterize the frequency dynamics of the ICP and pathologic LV vibration motion. Descriptions of exemplary devices are representative of acceleration sensing devices for the ICP and pathologic heart sounds.
- An acceleration sensor may be incorporated into a catheter for insertion into the LV veins such as the coronary sinus, great cardiac veins, or tributary vessels of these veins. The acceleration sensor may also be incorporated into a probe inserted into the esophagus, which lies immediately behind the posterior surface of the heart. The acceleration sensor may be a single dual axis sensor oriented perpendicularly to the long axis of the catheter. This orientation of the sensor allows the measurement of longitudinal and radial acceleration signals, which predominate in the heart, from the coronary sinus and great cardiac vein. The catheter probe may have a guidewire lumen; however this may not be required for an esophageal probe. The catheter or esophageal probe may monitor the frequency dynamics of the ICP and assess LV function. The esophageal probe could be used to monitor the ICP and third and fourth heart sounds to detect ischemia, for example during surgical procedures. For example, a decrease in amplitude of the ICP signal as measured by the esophageal probe could be indicative of ischemia. Because the esophageal probe would not move with heart contraction and the patient would be still during surgery, more accurate amplitude measures could be obtained.
- In addition the catheter and esophageal probe may be used to identify target LV pacing regions for CRT using a pacing guide wire. Referring to
FIG. 4 (A)-(E), aguide catheter 102 is shown with aproximal end 104. Anacceleration sensing catheter 100, that may be inserted into theguide catheter 102, is shown with a pacingguidewire port 114 and aguidewire lumen 108. The guidewire lumen may have a diameter of, e.g., 0.014″ to 0.038″. Thecatheter 100 also has asensor assembly 106 that may have one, two, or three acceleration sensors disposed within, the sensors being disposed perpendicularly to each other. Thecatheter 100 may have a bend near the distal end thereof, as shown inFIG. 4 (B). The bend may be from 0 degrees to 90 degrees. At the proximal end ofcatheter 100 is also disposed a power source such as abattery 126, a connector for low frequency (<20 Hz) signals 124, a connector for mid-frequency (20 Hz to 150 Hz) signals 122, and a connector for high frequency (>150 Hz) signals 118. - A pacing
guidewire 120 is shown inFIG. 4 (C) having aninsulated region 128 and anuninsulated region 132 for pacing. Aflexible conductor 134 is disposed at the proximal portion of theguidewire 120, as well as aconnector 136 to a pulse generator. -
FIG. 4 (D) shows a more detailed view of thecatheter 100, showing theguide lumen 108 and analternate sensor assembly 112. Thesensor assembly 112 is perpendicular to the long axis of thecatheter 100. - Referring to
FIG. 4 (E), themapping system 710 is made of anacceleration sensing catheter 700 and apacing guidewire 684. The pacing guidewire may be powered by apulse generator 712. - The output of the sensors may be connected to a signal conditioning module and
battery power module 714 prior to input into theelectrogram recording 716 anddisplay device 718. The output of the signal conditioning module may be analog signals if the electrocardiogram display is to be used. The signal conditioning module may also be used to correct or zero out the effects of gravity and the related tilt signal. Output from the signal conditioning module may also be digital. A microprocessing chip in the conditioning module may also perform functions such as forming a composite signal from multiple orientation axes and integration. The catheter within the guide catheter may have a guidewire lumen through which a pacing guidewire may be used to test pace target sites. This catheter may also have a port for contrast injection and may additionally have a balloon to perform an occlusive venogram. - A pacing guidewire would be positioned in various regions of the LV veins to elicit contractions. The LV response to this pacing may be measured by monitoring the frequency dynamics of the vibrational motion during ICP with the catheter.
FIG. 5 indicates this technique. In particular, the figure shows improved myocardial funcation post-stimulation as determined by an increase in the peak frequency of the isovolumic contraction phase. The left side ofFIG. 5 shows the pre-stimulation signal, and the right side shows the post-stimulation signal. As can be seen, the peak frequency increases post-stimulation from about 80 Hz to about 170 Hz (note that the peak frequency is related to the time interval of the threshold crossing). Also seen is a shortening of the time interval of the isovolumic contraction phase from about 100 ms to about 75 ms. The isovolumic contraction phase signal was acquired by sampling over a 100 ms time period after the onset of the QRS ECG signal. - Alternatively the frequency dynamics or amplitude could be measured with the esophageal probe. LV regions associated with changes in the ICP frequency indicative of improved LV function would be target pacing regions. For example, an increase in the peak frequency, the rate of change of the frequency over time, a reduction in the baseline frequency, or some combination of the three may be indicative of improved LV function. Similarly, the location of implantation and pacing of the RV lead or right atrial lead may also be optimized by test pacing and monitoring the frequency dynamics of the ICP.
- The change in the presence or frequency of the third or fourth heart sounds may also be indicative of a favorable response to pacing and hence help identify a target pacing region. Changes in the frequency and duration of vibration motion related to mitral valve regurgitation may also help guide therapy and target pacing regions. Thus a reduction in the frequency or duration of the signal may be indicative of a favorable response.
- In more detail, referring to
FIG. 6 , which shows myocardial motion mapping, display output, and target pacing identification through a roving pace guidewire, changes or variables indicative of a favorable LV functional response may be sensed at the low, mid, and high frequency ranges. In the figure, “MVR” refers to mitral valve regurgitation, “IVC” refers to isovolumic contraction, and “IVR” refers to isovolumic relaxation. The top curve isECG 556,curve 558 shows the velocity or LV displacement, obtained by integrating the acceleration signal,curve 562 shows LV function, andcurve 562 shows the sounds of mitral valve regurgitation. -
ECG 556 shows the QRS and T waves along with apacing spike 566 which is delivered in the LV vein region. Examination ofcurve 558 shows a delayedonset motion 568 but a lessened delayedonset motion 572 following the pacing spike.Curve 562 shows a value ofejection phase 574, as measured by the time between the MVC or IVC and the AVC or IVR, and then a longer ejection phase 576. Here the MPI can be seen to be MPI=(a+b)/c.Curve 564 shows a reducedMVR signal 578 as compared to thepre-pacing MVR signal 582. Finally, it is noted that paced signal shows no third heart sound. - The accelerometer for monitoring the frequency dynamics of heart sounds may also be integrated into a pulse generator of a CRT/defibrillator device, including leadless defibrillator devices implanted subcutaneously over the chest. This device would be implanted subcutaneously on the chest or abdomen and would sense the vibrational motion of the heart sounds (S1, S2, S3, S4 and valvular murmurs) to characterize the peak amplitude and frequency. This pulse generator could perform software algorithms to characterize the frequency dynamics of these sounds and assess LV function and pathology including contractility, mitral regurgitation, LV thickening etc. The start of systole as measured by the cardiac electrogram (internally or externally measured by the IPG) could be used to synchronize the accelerometer sensor with the onset of systole. Thus the S1 vibrational motion as measured by the accelerometer would occur within a few milliseconds of the sensed electrogram. Thereafter, additional vibrational motion (S2, S3, and S4 and murmurs) could be identified based on there occurrence after the electrogram and S1. Additional a time window of sensing with the acceleration sensor (eg. 100 ms) could be sensed to measure only the S1. with the This information could be uploaded via a radiofrequency link to provide a read out to the physician for monitoring purposes. The RF communication device that would acquire the data from the pulse generator could reside at the patients home and be transmitted to a physician or central monitoring station via the internet or a phone line link. The accelerometer could be used to sense that the patient in whom the device is implanted is not moving and is in the proper orientation (eg. upright or lying flat) prior to the acquisition of the heart function data.
- A stand alone implantable accelerometer device (IAD) (i.e. not incorporated into the IPG/CRT device) could also be implanted subcutaneously or subpectorally and not require an transvenous lead or extension. For example, referring to
FIG. 7 (B), a subpectorally-placedIAD 208 may be disposed adjacent thepectoral muscle 210 of a patient. Thedevice 208 may have anacceleration sensor 220, an RFcommunications transceiver chip 214 andantenna 212, signal processing andcontrol circuit 218 with digitalmemory storage capacity 222, and abattery 216. Referring toFIG. 7 (A), thedevice 208 may be contained in a hermetically sealedtitanium shell 202. The device could have a curved form factor as shown inFIG. 7 (A) to lie flat along the chest. The antenna could be wire wound or integrated onto the communications chip. The sensor may be a low-power consumption 3-axis MEMs device. The device may sense at a frequency greater than about 20 Hz to avoid acceleration signals due to respiration or displacement motion of the heart.Optional electrodes FIG. 7 (A), the electrodes would reside on the side of the device that is oriented toward the heart. 3-7 years of battery life may be provided, although variations are within the scope of the invention. Low power RF transceiver chips (applications specific integrated circuit or ASIC), such as that produced by Zarlink Semiconductor of San Diego, Calif. (e.g., model number ZL 70100) can improve battery life and data transmission of the device. The device need not require leads that extend into the heart and may reside in proximity to the left ventricle after subcutaneous or subpectoral implantation. The device may sense and measure vibrational data related to LV function and pathology such as frequency dynamics, time intervals, and peak amplitude of the ICP, S1, S2, S3, S4, and valvular murmurs. The surface of the device oriented toward the heart may have electrodes for sensing the surface electrocardiogram and the onset of the QRS. Similar to the inventor's prior applications, incorporated by reference above, this allows for the identification of the S1 as the vibrational signal immediately following the QRS. The subsequent vibrational signals could also be identified and time windows of sensing could also be incorporated to focus on the desired heart sound/vibrational motion. A narrow window of sensing that ascertains only the S1 vibrational signal may be preferred to avoid signal distortion or noise caused by movement of the heart against the chest during displacement or ejection. The S1 may be sensed and averaged over several to many beats. The vibrational motion could be sensed continuously or periodically. Periodic sensing may be used to extend battery life. The data may be collected at the same time during each day (e.g., at bedtime during quiet resting). The acceleration data could be stored or uploaded via an RF link in real time. The accelerometer could be battery-powered or inductively-powered with an RF coil. The data could be periodically or in real time uploaded with an RF link to a signal processing station for monitoring of the LV function such as contractility and pathology such as LV mass/thickness and valvular murmurs. The uploaded data could be sent via the internet to a physician or central monitoring station or both. The device could also interface with a cell phone type device for the same purpose of uploading data from the IAD. - Analysis of the frequency dynamics of the ICP (catheter or esophageal probe) could also be used to optimize the pacing timing intervals for CRT (A-V and V-V). Thus the V-V timing could be set to 0 ms (both ventricles paced simultaneously), and the AV delay could be varied between about 100 and 140 ms. The AV delay that provides a the highest peak frequency (or some other measure of improved cardiac function) during ICP could be chosen. Subsequently the A-V delay would be fixed at the previously determined optimal value and the V-V delay could be varied between −30 ms (LV to RV; thus −30 means the RV was paced 30 ms before the LV) to +30 ms LV to RV. Again the interval causing the highest peak frequency during ICP may be chosen. An automated system could run through the various pacing timing intervals and monitor the frequency dynamics of the ICP and provide optimal timing intervals.
- The acceleration sensor may also be incorporated into the lead of a CRT or CCM device. The sensor may monitor the frequency dynamics of the ICP to ascertain cardiac function in a manner similar to the above. The sensor could also be used to test different timing intervals for the atrioventricular and interventricular timing. The sensor may also be integrated into other implantable devices such as cardiac stents or epicardial leads to monitor cardiac function through analysis of the frequency dynamics of the ICP and pathologic heart sounds.
-
FIG. 8 shows how information from the acceleration sensor can be employed to develop a predictive algorithm for determining CRT response. The peak amplitude and peak frequency are seen atLV site # 3. A linear threshold relationship, or other such relationship, may be employed to determine when LV lead placement is acceptable for any given patient. If the amplitude is high enough at a certain frequency, and thus is above the linear threshold, then the response may be deemed to be good and the site chosen as a location for an LV lead. - The invention has been described with respect to certain embodiments. It will be clear to one of ordinary skill in the art given this disclosure that variations may be made to these embodiments. Accordingly, the scope of the invention is to be limited only by the claims appended hereto.
Claims (42)
1. A system for monitoring cardiac function, comprising:
a catheter component, the catheter component including:
a portion for insertion within or on a patient's heart, the insertion portion including an acceleration sensor;
an external portion including a connector to carry signals from the acceleration sensor;
a signal receiving and analysis component, the signal receiving and analysis component including:
a frequency analyzer to analyze the frequency dynamics of at least the S1 heart sound as measured by the acceleration sensor.
2. The device of claim 1 , wherein the sensor measures acceleration in three perpendicular components.
3. The device of claim 1 , wherein the frequency analyzer analyzes the frequency dynamics of the S1 heart sound as well as the frequency dynamics of at least one other heart sound.
4. The device of claim 1 , wherein the sensor is synchronized with a cardiac electrical signal indicative of the onset of myocardial contraction.
5. The device of claim 1 , wherein the cardiac function monitored is heart failure.
6. The device of claim 1 , wherein the frequencies analyzed are greater than about 20 Hz.
7. The device of claim 4 , further comprising an ECG component to measure an ECG of the patient, and wherein the sensor is synchronized with the R-wave measured by the ECG.
8. The device of claim 7 , wherein the signal receiving and analysis component further comprises a circuit implemented in hardware, software, firmware, or a combination of the above, to analyze the frequency change of the signal measured by the sensor.
9. A method for monitoring cardiac function, comprising:
inserting a catheter into a patient, a distal tip of the catheter including a section that resides within or on a patient's heart, the section including an acceleration sensor;
receiving signals from the acceleration sensor at a signal receiving and analysis component;
analyzing the frequency dynamics of at least the S1 heart sound as measured by the acceleration sensor.
10. The method of claim 9 , further comprising analyzing the frequency dynamics of at least one other heart sound besides the S1.
11. The method of claim 9 , wherein the cardiac function monitored is heart failure.
12. A system for optimizing CRT lead placement and/or CRT device timing intervals, comprising:
a test pacing component to perform test pacing of a patient's heart;
a catheter component, the catheter component including:
a portion for insertion within or on a patient's heart, the insertion portion including an acceleration sensor to monitor heart sounds responding to the test pacing;
an external portion including a connector to carry signals from the acceleration sensor;
a signal receiving and analysis component, the signal receiving and analysis component including:
a frequency analyzer to analyze the frequency dynamics of at least the S1 heart sound as measured by the acceleration sensor in response to the test pacing.
13. The system of claim 12 , wherein the sensor measures acceleration in three perpendicular components.
14. The system of claim 12 , wherein the frequency analyzer analyzes the frequency dynamics of the S1 heart sound as well as the frequency dynamics of at least one other heart sound.
15. The system of claim 12 , wherein the sensor is synchronized with a pacing spike from the test pacing component.
16. The system of claim 14 , wherein the frequencies analyzed include those at frequencies greater than about 20 Hz.
17. The system of claim 12 , wherein the test pacing component is a pacing guidewire.
18. A method for optimizing CRT lead placement and/or CRT device timing intervals, comprising:
inserting a catheter into a patient, a distal tip of the catheter including a section that resides within or on a patient's heart, the section including an acceleration sensor;
inserting a test pacing component within or on a patient's heart;
test pacing the patient's heart;
receiving signals from the acceleration sensor at a signal receiving and analysis component in response to the test pacing;
analyzing the frequency dynamics of at least the S1 heart sound as measured by the acceleration sensor in response to the test pacing.
19. The method of claim 18 , further comprising analyzing the frequency dynamics of at least one other heart sound besides the S1.
20. A system for monitoring cardiac function, comprising:
an implantable component, the implantable component including an acceleration sensor and a transmitter;
a signal receiving and analysis component, the signal receiving and analysis component including:
a receiver to receive signals from the transmitter; and
a frequency analyzer to analyze the frequency dynamics of at least the S1 heart sound as measured by the acceleration sensor.
21. The system of claim 20 , wherein the sensor measures acceleration in three perpendicular components.
22. The system of claim 20 , wherein the receiver is a wand-type receiver.
23. The system of claim 20 , wherein the implantable component further comprises a rechargeable battery and wherein the signal receiving and analysis component further comprises a wireless battery charger for recharging the battery.
24. The system of claim 20 , wherein the frequency analyzer analyzes the frequency dynamics of the S1 heart sound as well as the frequency dynamics of at least one other heart sound.
25. A method for monitoring cardiac function, comprising:
subcutaneously inserting an implantable component into a patient, the implantable component including an acceleration sensor and a transmitter;
receiving signals from the acceleration sensor at a signal receiving and analysis component;
receiving signals from a surface electrode disposed on the implantable component;
synchronizing the acceleration sensor with a signal received from the surface electrode corresponding to the onset of myocardial contraction;
analyzing the frequency dynamics of at least the S1 heart sound as measured by the acceleration sensor.
26. The method of claim 25 , further comprising analyzing the frequency dynamics of at least one other heart sound besides the S1.
27. The method of claim 25 , wherein the frequencies analyzed are greater than about 20 Hz.
28. A system for long-term monitoring of heart failure, comprising:
a. a housing, including:
a) an accelerometer;
b) A transceiver chip coupled to the accelerometer;
c) A battery coupled to the accelerometer;
b. wherein said housing is structured and configured to be implanted sub-cutaneously to monitor vibrational motion of the heart.
29. The system of claim 28 , further comprising at least one surface electrode structured within or on the housing for sensing a surface ECG.
30. The system of claim 28 , wherein the housing is integrated into a CRT device.
31. The system of claim 28 , wherein the housing is integrated into an implantable defibrillator.
32. The system of claim 31 , wherein the housing is integrated into a leadless implantable defibrillator.
33. The system of claim 29 , wherein the accelerometer senses vibrational motion in a time window of 100 milliseconds or less following a QRS of the surface ECG.
34. A method for monitoring cardiac function, comprising:
c. installing an acceleration sensor within or on a patient's heart;
d. installing a surface ECG electrode and measuring a patient's surface ECG; and
e. sensing vibrational motion in a time window following the R-wave measured by the surface ECG.
35. The method of claim 34 , wherein the sensing further comprises sensing acceleration in three perpendicular components.
36. The method of claim 34 , wherein the sensing is at a frequency greater than about 20 Hz.
37. The method of claim 34 , wherein the sensing further comprises sensing vibrational motion in a time window of 100 milliseconds or less following a QRS of the surface ECG.
38. The method of claim 34 , wherein the acceleration sensor and the surface ECG electrode are disposed within a single housing.
39. A method for optimizing CRT device timing intervals, comprising:
test pacing a patient's heart;
monitoring heart sounds responding to the test pacing using an acceleration sensor;
receiving signals corresponding to the monitored heart sounds;
analyzing the frequency dynamics of the received signals;
varying an AV or VV timing interval of the test pacing while analyzing the changes of the varying on the frequency dynamics.
40. The method of claim 39 , wherein the test pacing includes test pacing with a pacing guidewire.
41. The method of claim 39 , wherein the acceleration sensor is mounted on a catheter.
42. The method of claim 39 , wherein the receiving signals includes receiving signals including at least the S1 heart sound.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/347,623 US20060178589A1 (en) | 2005-02-07 | 2006-02-03 | Accelerometer-based monitoring of the frequency dynamics of the isovolumic contraction phase and pathologic cardiac vibrations |
PCT/US2006/004369 WO2006086435A2 (en) | 2005-02-07 | 2006-02-07 | Devices and methods for accelerometer-based characterization of cardiac function and monitoring of frequency dynamics of the isov |
US12/337,581 US20090306736A1 (en) | 2005-02-07 | 2008-12-17 | Accelerometer-based monitoring of the frequency dynamics of the isovolumic contraction phase and pathologic cardiac vibrations |
US13/230,084 US8831705B2 (en) | 2005-02-07 | 2011-09-12 | Devices and method for accelerometer-based characterization of cardiac synchrony and dyssynchrony |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65053205P | 2005-02-07 | 2005-02-07 | |
US65503805P | 2005-02-22 | 2005-02-22 | |
US65630705P | 2005-02-25 | 2005-02-25 | |
US65776605P | 2005-03-01 | 2005-03-01 | |
US65965805P | 2005-03-08 | 2005-03-08 | |
US66378805P | 2005-03-21 | 2005-03-21 | |
US66932405P | 2005-04-07 | 2005-04-07 | |
US67756905P | 2005-05-04 | 2005-05-04 | |
US68067305P | 2005-05-13 | 2005-05-13 | |
US11/347,623 US20060178589A1 (en) | 2005-02-07 | 2006-02-03 | Accelerometer-based monitoring of the frequency dynamics of the isovolumic contraction phase and pathologic cardiac vibrations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/396,420 Continuation-In-Part US8118751B2 (en) | 2005-02-07 | 2009-03-02 | Devices and methods for accelerometer-based characterization of cardiac function and identification of LV target pacing zones |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/337,581 Continuation US20090306736A1 (en) | 2005-02-07 | 2008-12-17 | Accelerometer-based monitoring of the frequency dynamics of the isovolumic contraction phase and pathologic cardiac vibrations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060178589A1 true US20060178589A1 (en) | 2006-08-10 |
Family
ID=36780822
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/318,325 Abandoned US20060178586A1 (en) | 2005-02-07 | 2005-12-23 | Devices and methods for accelerometer-based characterization of cardiac function and identification of LV target pacing zones |
US11/347,623 Abandoned US20060178589A1 (en) | 2005-02-07 | 2006-02-03 | Accelerometer-based monitoring of the frequency dynamics of the isovolumic contraction phase and pathologic cardiac vibrations |
US12/337,581 Abandoned US20090306736A1 (en) | 2005-02-07 | 2008-12-17 | Accelerometer-based monitoring of the frequency dynamics of the isovolumic contraction phase and pathologic cardiac vibrations |
US12/396,420 Expired - Fee Related US8118751B2 (en) | 2005-02-07 | 2009-03-02 | Devices and methods for accelerometer-based characterization of cardiac function and identification of LV target pacing zones |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/318,325 Abandoned US20060178586A1 (en) | 2005-02-07 | 2005-12-23 | Devices and methods for accelerometer-based characterization of cardiac function and identification of LV target pacing zones |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/337,581 Abandoned US20090306736A1 (en) | 2005-02-07 | 2008-12-17 | Accelerometer-based monitoring of the frequency dynamics of the isovolumic contraction phase and pathologic cardiac vibrations |
US12/396,420 Expired - Fee Related US8118751B2 (en) | 2005-02-07 | 2009-03-02 | Devices and methods for accelerometer-based characterization of cardiac function and identification of LV target pacing zones |
Country Status (2)
Country | Link |
---|---|
US (4) | US20060178586A1 (en) |
WO (1) | WO2006086435A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080287812A1 (en) * | 2007-05-16 | 2008-11-20 | Parlikar Tushar A | Systems and Methods for Model-Based Estimation of Cardiac Output and Total Peripheral Resistance |
US20080287753A1 (en) * | 2007-05-16 | 2008-11-20 | Parlikar Tushar A | System and method for prediction and detection of circulatory shock |
WO2008144490A1 (en) * | 2007-05-16 | 2008-11-27 | Massachusetts Instutute Of Technology | Systems and methods for model-based estimation of cardiac ejection fraction, cardiac contractility, and ventricular end-diastolic volume |
US20090036941A1 (en) * | 2007-07-31 | 2009-02-05 | Giorgio Corbucci | Cardiac resynchronization therapy for patients with right bundle branch block |
WO2009029943A1 (en) * | 2007-08-31 | 2009-03-05 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Implantable device, system including same, and method utilizing same |
US20090157136A1 (en) * | 2007-02-16 | 2009-06-18 | Pacesetter, Inc. | Motion-based optimization for placement of cardiac stimulation electrodes |
US20090254140A1 (en) * | 2007-02-16 | 2009-10-08 | Pacesetter, Inc. | Cardiac resynchronization therapy optimization using parameter estimation from realtime electrode motion tracking |
US20100069980A1 (en) * | 2008-09-16 | 2010-03-18 | Stahmann Jeffrey E | Cardiac function management integrating cardiac contractility modulation |
US8790264B2 (en) | 2010-05-27 | 2014-07-29 | Biomedical Acoustics Research Company | Vibro-acoustic detection of cardiac conditions |
US8972009B2 (en) | 2010-12-22 | 2015-03-03 | Pacesetter, Inc. | Systems and methods for determining optimal interventricular pacing delays based on electromechanical delays |
US20160051823A1 (en) * | 2014-08-22 | 2016-02-25 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker having a sensor with a lower power mode |
US10384058B2 (en) | 2017-06-16 | 2019-08-20 | Cardiaccs As | Methods and devices for securing a sensor at the heart |
US11660004B2 (en) * | 2016-10-27 | 2023-05-30 | City University Of Hong Kong | System, device and sensor for monitoring circulatory conditions and a method for manufacturing the same |
Families Citing this family (215)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005027998A2 (en) | 2003-09-16 | 2005-03-31 | Cardiomems, Inc. | Implantable wireless sensor |
US8026729B2 (en) | 2003-09-16 | 2011-09-27 | Cardiomems, Inc. | System and apparatus for in-vivo assessment of relative position of an implant |
US7572228B2 (en) | 2004-01-13 | 2009-08-11 | Remon Medical Technologies Ltd | Devices for fixing a sensor in a lumen |
US8172761B1 (en) | 2004-09-28 | 2012-05-08 | Impact Sports Technologies, Inc. | Monitoring device with an accelerometer, method and system |
US8915859B1 (en) | 2004-09-28 | 2014-12-23 | Impact Sports Technologies, Inc. | Monitoring device, system and method for a multi-player interactive game |
US7432723B2 (en) * | 2004-11-01 | 2008-10-07 | Cardiomems, Inc. | Coupling loop |
US10390714B2 (en) | 2005-01-12 | 2019-08-27 | Remon Medical Technologies, Ltd. | Devices for fixing a sensor in a lumen |
US7962208B2 (en) | 2005-04-25 | 2011-06-14 | Cardiac Pacemakers, Inc. | Method and apparatus for pacing during revascularization |
CA2613241A1 (en) | 2005-06-21 | 2007-01-04 | Cardiomems, Inc. | Method of manufacturing implantable wireless sensor for in vivo pressure measurement |
US8068908B2 (en) * | 2005-11-30 | 2011-11-29 | St. Jude Medical Ab | Implantable cardiac stimulator, system, device and method for monitoring cardiac synchrony |
US20100222836A1 (en) * | 2005-11-30 | 2010-09-02 | Karin Jarverud | Implantable cardiac stimulator, device and method for monitoring the heart cycle in a human heart |
US8060214B2 (en) | 2006-01-05 | 2011-11-15 | Cardiac Pacemakers, Inc. | Implantable medical device with inductive coil configurable for mechanical fixation |
US20070219592A1 (en) * | 2006-02-28 | 2007-09-20 | Physical Logic Ag | Cardiac Pacemaker and/or ICD Control and Monitor |
US7873410B2 (en) * | 2006-04-26 | 2011-01-18 | Medtronic, Inc. | Implantable medical device with electromechanical delay measurement for lead position and ventricular |
EP2037999B1 (en) | 2006-07-07 | 2016-12-28 | Proteus Digital Health, Inc. | Smart parenteral administration system |
US20080058772A1 (en) * | 2006-08-31 | 2008-03-06 | Robertson Timothy L | Personal paramedic |
EP2060014B1 (en) | 2006-09-08 | 2012-01-25 | CardioMems, Inc. | Physiological data acquisition and management system for use with an implanted wireless sensor |
EP2061373B1 (en) | 2006-09-15 | 2011-07-20 | Cardiac Pacemakers, Inc. | Anchor for an implantable medical device |
US8676349B2 (en) | 2006-09-15 | 2014-03-18 | Cardiac Pacemakers, Inc. | Mechanism for releasably engaging an implantable medical device for implantation |
US20100135548A1 (en) * | 2006-10-04 | 2010-06-03 | Koninklijke Philips Electronics N.V. | Medical Imaging System |
WO2008057720A1 (en) * | 2006-11-08 | 2008-05-15 | Cardiac Pacemakers, Inc. | Implant for securing a sensor in a vessel |
US8016764B1 (en) * | 2006-11-08 | 2011-09-13 | Pacesetter, Inc. | Systems and methods for evaluating ventricular dyssynchrony using atrial and ventricular pressure measurements obtained by an implantable medical device |
US7848822B2 (en) * | 2006-11-14 | 2010-12-07 | Cardiac Pacemakers, Inc. | Cardiac force sensor and methods of use |
WO2008070189A2 (en) | 2006-12-06 | 2008-06-12 | The Cleveland Clinic Foundation | Method and system for treating acute heart failure by neuromodulation |
US8229557B2 (en) | 2007-03-29 | 2012-07-24 | Cardiac Pacemakers, Inc. | Estimating acute response to cardiac resynchronization therapy |
US7912544B1 (en) * | 2007-04-20 | 2011-03-22 | Pacesetter, Inc. | CRT responder model using EGM information |
US8204599B2 (en) | 2007-05-02 | 2012-06-19 | Cardiac Pacemakers, Inc. | System for anchoring an implantable sensor in a vessel |
JP2010528814A (en) | 2007-06-14 | 2010-08-26 | カーディアック ペースメイカーズ, インコーポレイテッド | Multi-element acoustic recharging system |
EP2217144A1 (en) * | 2007-10-03 | 2010-08-18 | Medtronic, Inc. | Selecting cardiac pacing sites |
US8180428B2 (en) * | 2007-10-03 | 2012-05-15 | Medtronic, Inc. | Methods and systems for use in selecting cardiac pacing sites |
JP5243548B2 (en) | 2007-10-25 | 2013-07-24 | プロテウス デジタル ヘルス, インコーポレイテッド | Fluid communication port for information systems |
WO2009067463A1 (en) * | 2007-11-19 | 2009-05-28 | Proteus Biomedical, Inc. | Body-associated fluid transport structure evaluation devices |
DE102007057227B4 (en) * | 2007-11-28 | 2018-08-02 | Biotronik Se & Co. Kg | Cardiac stimulation arrangement |
US8287458B2 (en) | 2008-04-25 | 2012-10-16 | Pacesetter, Inc. | Coronary venous system pressure sensing |
US8019409B2 (en) * | 2008-06-09 | 2011-09-13 | Pacesetter, Inc. | Cardiac resynchronization therapy optimization using electromechanical delay from realtime electrode motion tracking |
US8014864B2 (en) * | 2008-06-17 | 2011-09-06 | Pacesetter, Inc. | Cardiomechanical assessment for cardiac resynchronization therapy |
US8639357B2 (en) | 2008-06-19 | 2014-01-28 | Cardiac Pacemakers, Inc. | Pacing catheter with stent electrode |
US8457738B2 (en) | 2008-06-19 | 2013-06-04 | Cardiac Pacemakers, Inc. | Pacing catheter for access to multiple vessels |
US9037235B2 (en) | 2008-06-19 | 2015-05-19 | Cardiac Pacemakers, Inc. | Pacing catheter with expandable distal end |
US9409012B2 (en) | 2008-06-19 | 2016-08-09 | Cardiac Pacemakers, Inc. | Pacemaker integrated with vascular intervention catheter |
US8244352B2 (en) | 2008-06-19 | 2012-08-14 | Cardiac Pacemakers, Inc. | Pacing catheter releasing conductive liquid |
EP2296536A1 (en) | 2008-07-15 | 2011-03-23 | Cardiac Pacemakers, Inc. | Implant assist apparatus for acoustically enabled implantable medical device |
US9717914B2 (en) * | 2008-09-16 | 2017-08-01 | Pacesetter, Inc. | Use of cardiohemic vibration for pacing therapies |
IT1393012B1 (en) | 2008-12-16 | 2012-04-11 | Tre Esse Progettazione Biomedica S R L | IMPLANTABLE TELEMETRIC DEVICE FOR HEART MONITORING. |
WO2010093489A2 (en) | 2009-02-13 | 2010-08-19 | Cardiac Pacemakers, Inc. | Deployable sensor platform on the lead system of an implantable device |
US8301267B2 (en) * | 2009-09-18 | 2012-10-30 | Cardiac Pacemakers, Inc. | Method and apparatus for sensing mechanical energy of an implantable lead |
US8187199B2 (en) * | 2009-11-05 | 2012-05-29 | Cardiac Pacemakers, Inc. | Myocardial contractile reserve measured during activities of daily living |
CN102946798A (en) | 2010-02-01 | 2013-02-27 | 普罗秋斯数字健康公司 | Data gathering system |
EP2531096A4 (en) | 2010-02-01 | 2013-09-11 | Proteus Digital Health Inc | Two-wrist data gathering system |
EP2533853A4 (en) | 2010-02-12 | 2013-11-06 | Brigham & Womens Hospital | System and method for automated adjustment of cardiac resynchronization therapy control parameters |
US8626279B2 (en) * | 2010-02-22 | 2014-01-07 | Oslo Universitetssykehus Hf | Methods for estimating the risk for ventricular arrhythmias in a subject |
US8798721B2 (en) * | 2010-05-26 | 2014-08-05 | Dib Ultrasound Catheter, Llc | System and method for visualizing catheter placement in a vasculature |
US8092393B1 (en) | 2010-07-28 | 2012-01-10 | Impact Sports Technologies, Inc. | Monitoring device with an accelerometer, method and system |
EP2478935B1 (en) * | 2011-01-21 | 2017-08-23 | NeuroCardiac Innovations, LLC | Implantable cardiac devices with body orientation unit |
US9907972B2 (en) | 2011-01-21 | 2018-03-06 | Neurocardiac Innovations, Llc | Implantable cardiac devices and methods with body orientation unit |
US9174060B2 (en) | 2011-01-21 | 2015-11-03 | Neurocardiac Innovations, Llc | Implantable cardiac devices and methods |
US9144686B2 (en) | 2011-01-21 | 2015-09-29 | Neurocardiac Innovations, Llc | Implantable medical device with external access for recharging and data communication |
US9216296B2 (en) | 2011-01-21 | 2015-12-22 | Neurocardiac Innovations, Llc | Implantable medical device capable of preserving battery energy to extend its operating life |
US8972228B2 (en) | 2011-05-03 | 2015-03-03 | Medtronic, Inc. | Assessing intra-cardiac activation patterns |
US9109902B1 (en) | 2011-06-13 | 2015-08-18 | Impact Sports Technologies, Inc. | Monitoring device with a pedometer |
US8682436B2 (en) | 2011-12-23 | 2014-03-25 | Medtronic, Inc. | Detection of target vein for CRT therapy |
CN107260142B (en) | 2012-01-16 | 2020-10-20 | 瓦伦赛尔公司 | Reduction of physiological index errors using inertial frequency |
US10390762B2 (en) | 2012-01-16 | 2019-08-27 | Valencell, Inc. | Physiological metric estimation rise and fall limiting |
US20130289377A1 (en) | 2012-04-27 | 2013-10-31 | Medtronic, Inc. | Method and apparatus for cardiac function monitoring |
US9351687B2 (en) * | 2012-06-28 | 2016-05-31 | Volcano Corporation | Intravascular devices, systems, and methods |
US9801721B2 (en) * | 2012-10-12 | 2017-10-31 | St. Jude Medical, Cardiology Division, Inc. | Sizing device and method of positioning a prosthetic heart valve |
US20140121721A1 (en) * | 2012-10-30 | 2014-05-01 | Medtronic, Inc. | Apparatus and method for placement of lead for cardiac resynchronization therapy |
WO2014109982A2 (en) * | 2013-01-09 | 2014-07-17 | Valencell Inc. | Cadence detection based on inertial harmonics |
AU2014209143B2 (en) | 2013-01-24 | 2018-05-24 | Alio, Inc. | Method and apparatus for measuring flow through a lumen |
US9282916B2 (en) * | 2013-03-01 | 2016-03-15 | Pacesetter, Inc. | Vascular branch characterization |
US9740828B2 (en) * | 2013-03-13 | 2017-08-22 | SMRxT Inc. | Medicine container with an orientation sensor |
US9278219B2 (en) | 2013-03-15 | 2016-03-08 | Medtronic, Inc. | Closed loop optimization of control parameters during cardiac pacing |
US9931048B2 (en) | 2013-04-30 | 2018-04-03 | Medtronic, Inc. | Systems, methods, and interfaces for identifying effective electrodes |
US10064567B2 (en) | 2013-04-30 | 2018-09-04 | Medtronic, Inc. | Systems, methods, and interfaces for identifying optimal electrical vectors |
US9877789B2 (en) | 2013-06-12 | 2018-01-30 | Medtronic, Inc. | Implantable electrode location selection |
US10251555B2 (en) | 2013-06-12 | 2019-04-09 | Medtronic, Inc. | Implantable electrode location selection |
US9486151B2 (en) | 2013-06-12 | 2016-11-08 | Medtronic, Inc. | Metrics of electrical dyssynchrony and electrical activation patterns from surface ECG electrodes |
US9295397B2 (en) | 2013-06-14 | 2016-03-29 | Massachusetts Institute Of Technology | Method and apparatus for beat-space frequency domain prediction of cardiovascular death after acute coronary event |
US9278220B2 (en) | 2013-07-23 | 2016-03-08 | Medtronic, Inc. | Identification of healthy versus unhealthy substrate for pacing from a multipolar lead |
US9282907B2 (en) | 2013-07-23 | 2016-03-15 | Medtronic, Inc. | Identification of healthy versus unhealthy substrate for pacing from a multipolar lead |
US9265955B2 (en) | 2013-07-26 | 2016-02-23 | Medtronic, Inc. | Method and system for improved estimation of time of left ventricular pacing with respect to intrinsic right ventricular activation in cardiac resynchronization therapy |
US9265954B2 (en) | 2013-07-26 | 2016-02-23 | Medtronic, Inc. | Method and system for improved estimation of time of left ventricular pacing with respect to intrinsic right ventricular activation in cardiac resynchronization therapy |
DE102013014685B4 (en) | 2013-09-05 | 2018-01-04 | Universität Stuttgart | Urokatheter |
US9320446B2 (en) | 2013-12-09 | 2016-04-26 | Medtronic, Inc. | Bioelectric sensor device and methods |
US9993172B2 (en) | 2013-12-09 | 2018-06-12 | Medtronic, Inc. | Noninvasive cardiac therapy evaluation |
CN106102830B (en) | 2014-01-10 | 2019-07-16 | 心脏起搏器股份公司 | For improving the method and system of the communication between medical device |
EP3092034B1 (en) | 2014-01-10 | 2019-10-30 | Cardiac Pacemakers, Inc. | Systems for detecting cardiac arrhythmias |
EP3146896B1 (en) | 2014-02-28 | 2020-04-01 | Valencell, Inc. | Method and apparatus for generating assessments using physical activity and biometric parameters |
US9776009B2 (en) | 2014-03-20 | 2017-10-03 | Medtronic, Inc. | Non-invasive detection of phrenic nerve stimulation |
US10307070B2 (en) | 2014-04-04 | 2019-06-04 | St. Jude Medical Coordination Center Bvba | Intravascular pressure and flow data diagnostic systems, devices, and methods |
CN111790047B (en) | 2014-05-22 | 2022-09-27 | 卡迪诺米克公司 | Catheter and catheter system for electrical neuromodulation |
US9179849B1 (en) | 2014-07-25 | 2015-11-10 | Impact Sports Technologies, Inc. | Mobile plethysmographic device |
US9591982B2 (en) | 2014-07-31 | 2017-03-14 | Medtronic, Inc. | Systems and methods for evaluating cardiac therapy |
US9764143B2 (en) | 2014-08-15 | 2017-09-19 | Medtronic, Inc. | Systems and methods for configuration of interventricular interval |
US9586052B2 (en) | 2014-08-15 | 2017-03-07 | Medtronic, Inc. | Systems and methods for evaluating cardiac therapy |
US9707400B2 (en) | 2014-08-15 | 2017-07-18 | Medtronic, Inc. | Systems, methods, and interfaces for configuring cardiac therapy |
US9586050B2 (en) | 2014-08-15 | 2017-03-07 | Medtronic, Inc. | Systems and methods for configuration of atrioventricular interval |
EP3185952B1 (en) | 2014-08-28 | 2018-07-25 | Cardiac Pacemakers, Inc. | Implantable cardiac rhythm system and an associated method for triggering a blanking period through a second device |
EP3194017A1 (en) | 2014-09-08 | 2017-07-26 | Cardionomic, Inc. | Methods for electrical neuromodulation of the heart |
WO2016073509A1 (en) | 2014-11-04 | 2016-05-12 | Cardiac Pacemakers, Inc. | Implantable medical devices and methods for making and delivering implantable medical devices |
CA2972459A1 (en) | 2015-01-05 | 2016-07-14 | CARDIONOMIC, Inc. | Cardiac modulation facilitation methods and systems |
US11253178B2 (en) | 2015-01-29 | 2022-02-22 | Medtronic, Inc. | Noninvasive assessment of cardiac resynchronization therapy |
EP3253450B1 (en) | 2015-02-06 | 2021-03-24 | Cardiac Pacemakers, Inc. | System for treating cardiac arrhythmias |
CN107206242B (en) | 2015-02-06 | 2020-10-30 | 心脏起搏器股份公司 | Systems and methods for safe delivery of electrical stimulation therapy |
WO2016130477A2 (en) | 2015-02-09 | 2016-08-18 | Cardiac Pacemakers, Inc. | Implantable medical device with radiopaque id tag |
CN104644157B (en) * | 2015-02-26 | 2017-05-10 | 首都医科大学附属北京安贞医院 | Special sacculus radiography electrophysiological mapping catheter for CRT (Cardiac Resynchronization Therapy) |
EP3265172B1 (en) | 2015-03-04 | 2018-12-19 | Cardiac Pacemakers, Inc. | Systems for treating cardiac arrhythmias |
US9924905B2 (en) * | 2015-03-09 | 2018-03-27 | Graftworx, Inc. | Sensor position on a prosthesis for detection of a stenosis |
CN107427222B (en) | 2015-03-18 | 2021-02-09 | 心脏起搏器股份公司 | Communication in a medical device system using link quality assessment |
US10050700B2 (en) | 2015-03-18 | 2018-08-14 | Cardiac Pacemakers, Inc. | Communications in a medical device system with temporal optimization |
US9757574B2 (en) | 2015-05-11 | 2017-09-12 | Rainbow Medical Ltd. | Dual chamber transvenous pacemaker |
WO2017031347A1 (en) | 2015-08-20 | 2017-02-23 | Cardiac Pacemakers, Inc. | Systems and methods for communication between medical devices |
CN108136186B (en) | 2015-08-20 | 2021-09-17 | 心脏起搏器股份公司 | System and method for communication between medical devices |
US9956414B2 (en) | 2015-08-27 | 2018-05-01 | Cardiac Pacemakers, Inc. | Temporal configuration of a motion sensor in an implantable medical device |
US9968787B2 (en) | 2015-08-27 | 2018-05-15 | Cardiac Pacemakers, Inc. | Spatial configuration of a motion sensor in an implantable medical device |
US10137305B2 (en) | 2015-08-28 | 2018-11-27 | Cardiac Pacemakers, Inc. | Systems and methods for behaviorally responsive signal detection and therapy delivery |
US10226631B2 (en) | 2015-08-28 | 2019-03-12 | Cardiac Pacemakers, Inc. | Systems and methods for infarct detection |
WO2017040115A1 (en) | 2015-08-28 | 2017-03-09 | Cardiac Pacemakers, Inc. | System for detecting tamponade |
WO2017044389A1 (en) | 2015-09-11 | 2017-03-16 | Cardiac Pacemakers, Inc. | Arrhythmia detection and confirmation |
CN108136185B (en) | 2015-10-08 | 2021-08-31 | 心脏起搏器股份公司 | Apparatus and method for adjusting pacing rate in an implantable medical device |
WO2017059569A1 (en) * | 2015-10-08 | 2017-04-13 | 深圳迈瑞生物医疗电子股份有限公司 | Pacing signal processing method, system and electrocardiogram monitor |
EP3389775B1 (en) | 2015-12-17 | 2019-09-25 | Cardiac Pacemakers, Inc. | Conducted communication in a medical device system |
US10905886B2 (en) | 2015-12-28 | 2021-02-02 | Cardiac Pacemakers, Inc. | Implantable medical device for deployment across the atrioventricular septum |
US10583303B2 (en) | 2016-01-19 | 2020-03-10 | Cardiac Pacemakers, Inc. | Devices and methods for wirelessly recharging a rechargeable battery of an implantable medical device |
US10350423B2 (en) | 2016-02-04 | 2019-07-16 | Cardiac Pacemakers, Inc. | Delivery system with force sensor for leadless cardiac device |
US10780279B2 (en) | 2016-02-26 | 2020-09-22 | Medtronic, Inc. | Methods and systems of optimizing right ventricular only pacing for patients with respect to an atrial event and left ventricular event |
US11219769B2 (en) | 2016-02-26 | 2022-01-11 | Medtronic, Inc. | Noninvasive methods and systems of determining the extent of tissue capture from cardiac pacing |
CA3015372A1 (en) | 2016-03-09 | 2017-09-14 | CARDIONOMIC, Inc. | Cardiac contractility neurostimulation systems and methods |
US11116988B2 (en) | 2016-03-31 | 2021-09-14 | Cardiac Pacemakers, Inc. | Implantable medical device with rechargeable battery |
US10729898B2 (en) | 2016-04-06 | 2020-08-04 | Cardiac Pacemakers, Inc. | Multi-site CRT capture verification |
US10668294B2 (en) | 2016-05-10 | 2020-06-02 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker configured for over the wire delivery |
US10328272B2 (en) | 2016-05-10 | 2019-06-25 | Cardiac Pacemakers, Inc. | Retrievability for implantable medical devices |
US10512784B2 (en) | 2016-06-27 | 2019-12-24 | Cardiac Pacemakers, Inc. | Cardiac therapy system using subcutaneously sensed P-waves for resynchronization pacing management |
WO2018009569A1 (en) | 2016-07-06 | 2018-01-11 | Cardiac Pacemakers, Inc. | Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system |
US10426962B2 (en) | 2016-07-07 | 2019-10-01 | Cardiac Pacemakers, Inc. | Leadless pacemaker using pressure measurements for pacing capture verification |
EP3487579B1 (en) | 2016-07-20 | 2020-11-25 | Cardiac Pacemakers, Inc. | System for utilizing an atrial contraction timing fiducial in a leadless cardiac pacemaker system |
CN109562269B (en) | 2016-08-19 | 2023-08-11 | 心脏起搏器股份公司 | Transseptal implantable medical device |
WO2018039322A1 (en) | 2016-08-24 | 2018-03-01 | Cardiac Pacemakers, Inc. | Cardiac resynchronization using fusion promotion for timing management |
US10780278B2 (en) | 2016-08-24 | 2020-09-22 | Cardiac Pacemakers, Inc. | Integrated multi-device cardiac resynchronization therapy using P-wave to pace timing |
WO2018049412A1 (en) | 2016-09-12 | 2018-03-15 | Graftworx, Inc. | Wearable device with multimodal diagnostics |
EP3515553B1 (en) | 2016-09-21 | 2020-08-26 | Cardiac Pacemakers, Inc. | Leadless stimulation device with a housing that houses internal components of the leadless stimulation device and functions as the battery case and a terminal of an internal battery |
US10758737B2 (en) | 2016-09-21 | 2020-09-01 | Cardiac Pacemakers, Inc. | Using sensor data from an intracardially implanted medical device to influence operation of an extracardially implantable cardioverter |
WO2018057626A1 (en) | 2016-09-21 | 2018-03-29 | Cardiac Pacemakers, Inc. | Implantable cardiac monitor |
WO2018081133A1 (en) | 2016-10-27 | 2018-05-03 | Cardiac Pacemakers, Inc. | Implantable medical device having a sense channel with performance adjustment |
WO2018081275A1 (en) | 2016-10-27 | 2018-05-03 | Cardiac Pacemakers, Inc. | Multi-device cardiac resynchronization therapy with timing enhancements |
WO2018081237A1 (en) | 2016-10-27 | 2018-05-03 | Cardiac Pacemakers, Inc. | Use of a separate device in managing the pace pulse energy of a cardiac pacemaker |
US10413733B2 (en) | 2016-10-27 | 2019-09-17 | Cardiac Pacemakers, Inc. | Implantable medical device with gyroscope |
JP7038115B2 (en) | 2016-10-27 | 2022-03-17 | カーディアック ペースメイカーズ, インコーポレイテッド | Implantable medical device with pressure sensor |
EP3532159B1 (en) | 2016-10-27 | 2021-12-22 | Cardiac Pacemakers, Inc. | Implantable medical device delivery system with integrated sensor |
WO2018081713A1 (en) | 2016-10-31 | 2018-05-03 | Cardiac Pacemakers, Inc | Systems for activity level pacing |
US10434317B2 (en) | 2016-10-31 | 2019-10-08 | Cardiac Pacemakers, Inc. | Systems and methods for activity level pacing |
US10583301B2 (en) | 2016-11-08 | 2020-03-10 | Cardiac Pacemakers, Inc. | Implantable medical device for atrial deployment |
US10632313B2 (en) | 2016-11-09 | 2020-04-28 | Cardiac Pacemakers, Inc. | Systems, devices, and methods for setting cardiac pacing pulse parameters for a cardiac pacing device |
WO2018094342A1 (en) | 2016-11-21 | 2018-05-24 | Cardiac Pacemakers, Inc | Implantable medical device with a magnetically permeable housing and an inductive coil disposed about the housing |
US10639486B2 (en) | 2016-11-21 | 2020-05-05 | Cardiac Pacemakers, Inc. | Implantable medical device with recharge coil |
US10894163B2 (en) | 2016-11-21 | 2021-01-19 | Cardiac Pacemakers, Inc. | LCP based predictive timing for cardiac resynchronization |
JP6781346B2 (en) | 2016-11-21 | 2020-11-04 | カーディアック ペースメイカーズ, インコーポレイテッド | Leadless cardiac pacemaker with multi-mode communication |
US10881869B2 (en) | 2016-11-21 | 2021-01-05 | Cardiac Pacemakers, Inc. | Wireless re-charge of an implantable medical device |
US11207532B2 (en) | 2017-01-04 | 2021-12-28 | Cardiac Pacemakers, Inc. | Dynamic sensing updates using postural input in a multiple device cardiac rhythm management system |
WO2018140797A1 (en) | 2017-01-26 | 2018-08-02 | Cardiac Pacemakers, Inc. | Leadless implantable device with detachable fixation |
EP3573706A1 (en) | 2017-01-26 | 2019-12-04 | Cardiac Pacemakers, Inc. | Intra-body device communication with redundant message transmission |
CN110234392B (en) | 2017-01-26 | 2023-08-11 | 心脏起搏器股份公司 | Leadless device with overmolded component |
AU2018214450B2 (en) * | 2017-02-06 | 2023-08-24 | Western Sydney Local Health District | Methods and apparatuses for monitoring cardiac dysfunction |
US10532213B2 (en) | 2017-03-03 | 2020-01-14 | Medtronic, Inc. | Criteria for determination of local tissue latency near pacing electrode |
US10987517B2 (en) | 2017-03-15 | 2021-04-27 | Medtronic, Inc. | Detection of noise signals in cardiac signals |
CN110740779B (en) | 2017-04-03 | 2024-03-08 | 心脏起搏器股份公司 | Cardiac pacemaker with pacing pulse energy modulation based on sensed heart rate |
US10905872B2 (en) | 2017-04-03 | 2021-02-02 | Cardiac Pacemakers, Inc. | Implantable medical device with a movable electrode biased toward an extended position |
EP3658017B1 (en) | 2017-07-28 | 2023-07-26 | Medtronic, Inc. | Generating activation times |
CN111050841B (en) | 2017-07-28 | 2023-09-26 | 美敦力公司 | Cardiac cycle selection |
EP3668592B1 (en) | 2017-08-18 | 2021-11-17 | Cardiac Pacemakers, Inc. | Implantable medical device with pressure sensor |
WO2019036568A1 (en) | 2017-08-18 | 2019-02-21 | Cardiac Pacemakers, Inc. | Implantable medical device with a flux concentrator and a receiving coil disposed about the flux concentrator |
AU2018333929A1 (en) * | 2017-09-13 | 2020-04-09 | CARDIONOMIC, Inc. | Neurostimulation systems and methods for affecting cardiac contractility |
WO2019060302A1 (en) | 2017-09-20 | 2019-03-28 | Cardiac Pacemakers, Inc. | Implantable medical device with multiple modes of operation |
US11185703B2 (en) | 2017-11-07 | 2021-11-30 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker for bundle of his pacing |
CN111417432A (en) | 2017-12-01 | 2020-07-14 | 心脏起搏器股份公司 | Leadless cardiac pacemaker with involution behavior |
EP3717064B1 (en) | 2017-12-01 | 2023-06-07 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials during ventricular filling from a ventricularly implanted leadless cardiac pacemaker |
WO2019108837A1 (en) | 2017-12-01 | 2019-06-06 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials within a search window from a ventricularly implanted leadless cardiac pacemaker |
EP3717063B1 (en) | 2017-12-01 | 2023-12-27 | Cardiac Pacemakers, Inc. | Systems for detecting atrial contraction timing fiducials and determining a cardiac interval from a ventricularly implanted leadless cardiac pacemaker |
US11419539B2 (en) | 2017-12-22 | 2022-08-23 | Regents Of The University Of Minnesota | QRS onset and offset times and cycle selection using anterior and posterior electrode signals |
US10786167B2 (en) | 2017-12-22 | 2020-09-29 | Medtronic, Inc. | Ectopic beat-compensated electrical heterogeneity information |
US10433746B2 (en) | 2017-12-22 | 2019-10-08 | Regents Of The University Of Minnesota | Systems and methods for anterior and posterior electrode signal analysis |
US10492705B2 (en) | 2017-12-22 | 2019-12-03 | Regents Of The University Of Minnesota | Anterior and posterior electrode signals |
US10799703B2 (en) | 2017-12-22 | 2020-10-13 | Medtronic, Inc. | Evaluation of his bundle pacing therapy |
WO2019136148A1 (en) | 2018-01-04 | 2019-07-11 | Cardiac Pacemakers, Inc. | Dual chamber pacing without beat-to-beat communication |
US11529523B2 (en) | 2018-01-04 | 2022-12-20 | Cardiac Pacemakers, Inc. | Handheld bridge device for providing a communication bridge between an implanted medical device and a smartphone |
US11957586B2 (en) | 2018-01-27 | 2024-04-16 | Mitre Medical Corp. | Epicardial valve repair system |
US10617318B2 (en) | 2018-02-27 | 2020-04-14 | Medtronic, Inc. | Mapping electrical activity on a model heart |
US10668290B2 (en) | 2018-03-01 | 2020-06-02 | Medtronic, Inc. | Delivery of pacing therapy by a cardiac pacing device |
US10918870B2 (en) | 2018-03-07 | 2021-02-16 | Medtronic, Inc. | Atrial lead placement for treatment of atrial dyssynchrony |
US11400296B2 (en) | 2018-03-23 | 2022-08-02 | Medtronic, Inc. | AV synchronous VfA cardiac therapy |
WO2019183514A1 (en) | 2018-03-23 | 2019-09-26 | Medtronic, Inc. | Vfa cardiac therapy for tachycardia |
US10780281B2 (en) | 2018-03-23 | 2020-09-22 | Medtronic, Inc. | Evaluation of ventricle from atrium pacing therapy |
US11235159B2 (en) | 2018-03-23 | 2022-02-01 | Medtronic, Inc. | VFA cardiac resynchronization therapy |
US11285312B2 (en) | 2018-03-29 | 2022-03-29 | Medtronic, Inc. | Left ventricular assist device adjustment and evaluation |
US10940321B2 (en) | 2018-06-01 | 2021-03-09 | Medtronic, Inc. | Systems, methods, and interfaces for use in cardiac evaluation |
US11304641B2 (en) | 2018-06-01 | 2022-04-19 | Medtronic, Inc. | Systems, methods, and interfaces for use in cardiac evaluation |
JP2021526394A (en) * | 2018-06-14 | 2021-10-07 | メドトロニック,インコーポレイテッド | Delivery of cardiac pacing therapy for cardiac remodeling |
CA3107959A1 (en) | 2018-08-13 | 2020-02-20 | CARDIONOMIC, Inc. | Systems and methods for affecting cardiac contractility and/or relaxation |
JP2022501085A (en) | 2018-09-26 | 2022-01-06 | メドトロニック,インコーポレイテッド | Capturing in ventricular cardiac therapy from the atria |
US11951313B2 (en) | 2018-11-17 | 2024-04-09 | Medtronic, Inc. | VFA delivery systems and methods |
CN113195047A (en) * | 2018-12-06 | 2021-07-30 | 美敦力公司 | Method and apparatus for establishing parameters for cardiac event detection |
US11679265B2 (en) | 2019-02-14 | 2023-06-20 | Medtronic, Inc. | Lead-in-lead systems and methods for cardiac therapy |
US11547858B2 (en) | 2019-03-29 | 2023-01-10 | Medtronic, Inc. | Systems, methods, and devices for adaptive cardiac therapy |
US11697025B2 (en) | 2019-03-29 | 2023-07-11 | Medtronic, Inc. | Cardiac conduction system capture |
US11213676B2 (en) | 2019-04-01 | 2022-01-04 | Medtronic, Inc. | Delivery systems for VfA cardiac therapy |
EP3965639A4 (en) | 2019-05-06 | 2022-12-07 | Cardionomic, Inc. | Systems and methods for denoising physiological signals during electrical neuromodulation |
US11712188B2 (en) | 2019-05-07 | 2023-08-01 | Medtronic, Inc. | Posterior left bundle branch engagement |
US11305127B2 (en) | 2019-08-26 | 2022-04-19 | Medtronic Inc. | VfA delivery and implant region detection |
US11497431B2 (en) | 2019-10-09 | 2022-11-15 | Medtronic, Inc. | Systems and methods for configuring cardiac therapy |
US11642533B2 (en) | 2019-11-04 | 2023-05-09 | Medtronic, Inc. | Systems and methods for evaluating cardiac therapy |
US11813466B2 (en) | 2020-01-27 | 2023-11-14 | Medtronic, Inc. | Atrioventricular nodal stimulation |
US11911168B2 (en) | 2020-04-03 | 2024-02-27 | Medtronic, Inc. | Cardiac conduction system therapy benefit determination |
US11717688B2 (en) | 2020-04-07 | 2023-08-08 | Medtronic, Inc. | Medical device and method for detecting atrioventricular block |
US11813449B2 (en) * | 2020-07-31 | 2023-11-14 | Medtronic, Inc. | Septal perforating vein pacing |
US11813464B2 (en) | 2020-07-31 | 2023-11-14 | Medtronic, Inc. | Cardiac conduction system evaluation |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5031614A (en) * | 1986-09-12 | 1991-07-16 | Eckhard Alt | Pacemaker rate control using amplitude and frequency of activity signal |
US5383473A (en) * | 1993-05-10 | 1995-01-24 | Pacesetter, Inc. | Rate-responsive implantable stimulation device having a miniature hybrid-mountable accelerometer-based sensor and method of fabrication |
US5425750A (en) * | 1993-07-14 | 1995-06-20 | Pacesetter, Inc. | Accelerometer-based multi-axis physical activity sensor for a rate-responsive pacemaker and method of fabrication |
US5454838A (en) * | 1992-07-27 | 1995-10-03 | Sorin Biomedica S.P.A. | Method and a device for monitoring heart function |
US5540727A (en) * | 1994-11-15 | 1996-07-30 | Cardiac Pacemakers, Inc. | Method and apparatus to automatically optimize the pacing mode and pacing cycle parameters of a dual chamber pacemaker |
US5549650A (en) * | 1994-06-13 | 1996-08-27 | Pacesetter, Inc. | System and method for providing hemodynamically optimal pacing therapy |
US5554177A (en) * | 1995-03-27 | 1996-09-10 | Medtronic, Inc. | Method and apparatus to optimize pacing based on intensity of acoustic signal |
US5628777A (en) * | 1993-07-14 | 1997-05-13 | Pacesetter, Inc. | Implantable leads incorporating cardiac wall acceleration sensors and method of fabrication |
US5715827A (en) * | 1994-09-02 | 1998-02-10 | Cardiometrics, Inc. | Ultra miniature pressure sensor and guide wire using the same and method |
US5792195A (en) * | 1996-12-16 | 1998-08-11 | Cardiac Pacemakers, Inc. | Acceleration sensed safe upper rate envelope for calculating the hemodynamic upper rate limit for a rate adaptive cardiac rhythm management device |
US6002963A (en) * | 1995-02-17 | 1999-12-14 | Pacesetter, Inc. | Multi-axial accelerometer-based sensor for an implantable medical device and method of measuring motion measurements therefor |
US6077236A (en) * | 1994-06-07 | 2000-06-20 | Cunningham; David | Apparatus for monitoring cardiac contractility |
US6275724B1 (en) * | 1998-03-27 | 2001-08-14 | Intravascular Research Limited | Medical ultrasonic imaging |
US20020016615A1 (en) * | 1998-05-08 | 2002-02-07 | Dev Nagendu B. | Electrically induced vessel vasodilation |
US6542775B2 (en) * | 1998-05-08 | 2003-04-01 | Cardiac Pacemakers, Inc. | Cardiac pacing using adjustable atrio-ventricular delays |
US6643548B1 (en) * | 2000-04-06 | 2003-11-04 | Pacesetter, Inc. | Implantable cardiac stimulation device for monitoring heart sounds to detect progression and regression of heart disease and method thereof |
US6650940B1 (en) * | 2000-02-02 | 2003-11-18 | Cardiac Pacemakers, Inc. | Accelerometer-based heart sound detection for autocapture |
US6667725B1 (en) * | 2002-08-20 | 2003-12-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Radio frequency telemetry system for sensors and actuators |
US7117035B2 (en) * | 2003-04-11 | 2006-10-03 | Cardiac Pacemakers, Inc. | Subcutaneous cardiac stimulation system with patient activity sensing |
US7270634B2 (en) * | 2003-03-27 | 2007-09-18 | Koninklijke Philips Electronics N.V. | Guidance of invasive medical devices by high resolution three dimensional ultrasonic imaging |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3695253A (en) * | 1970-06-29 | 1972-10-03 | Harold G Vielhauer | Apparatus for physiological investigation |
US4496361A (en) * | 1981-08-05 | 1985-01-29 | E. I. Du Pont De Nemours And Company | Platelet storage container |
US4763645A (en) * | 1987-08-25 | 1988-08-16 | Kapp Michael J | Tracheal tube filter |
US5268777A (en) * | 1987-12-23 | 1993-12-07 | Seiko Epson Corporation | Driving method of active matrix display having ferroelectric layer as active layer |
US4932407A (en) * | 1988-12-15 | 1990-06-12 | Medtronic, Inc. | Endocardial defibrillation electrode system |
IT1245814B (en) * | 1991-05-21 | 1994-10-18 | Sorin Biomedica Spa | RATE RESPONSIVE CARDIOSTIMULATOR DEVICE |
IT1260692B (en) * | 1993-10-05 | 1996-04-22 | Sorin Biomedica Spa | DEVICE FOR DETERMINING THE MYOCARDIC FUNCTION AND ITS PROCEDURE. |
US5705999A (en) * | 1995-06-05 | 1998-01-06 | Shell Oil Company | Engine operation detection |
US6053913A (en) * | 1998-09-10 | 2000-04-25 | Tu; Lily Chen | Rapid exchange stented balloon catheter having ablation capabilities |
US6466821B1 (en) * | 1999-12-08 | 2002-10-15 | Pacesetter, Inc. | AC/DC multi-axis accelerometer for determining patient activity and body position |
US6705999B2 (en) * | 2001-03-30 | 2004-03-16 | Guidant Corporation | Method and apparatus for determining the coronary sinus vein branch accessed by a coronary sinus lead |
US6665564B2 (en) * | 2001-05-21 | 2003-12-16 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system selecting A-V delay based on interval between atrial depolarization and mitral valve closure |
US7127289B2 (en) * | 2001-12-05 | 2006-10-24 | Cardiac Pacemakers, Inc. | Cardiac resynchronization system employing mechanical measurement of cardiac walls |
US7206634B2 (en) * | 2002-07-26 | 2007-04-17 | Cardiac Pacemakers, Inc. | Method and apparatus for optimizing cardiac pumping performance |
US20040260346A1 (en) * | 2003-01-31 | 2004-12-23 | Overall William Ryan | Detection of apex motion for monitoring cardiac dysfunction |
US6869404B2 (en) * | 2003-02-26 | 2005-03-22 | Medtronic, Inc. | Apparatus and method for chronically monitoring heart sounds for deriving estimated blood pressure |
US7610088B2 (en) * | 2003-02-28 | 2009-10-27 | Medtronic, Inc. | Method and apparatus for assessing left ventricular function and optimizing cardiac pacing intervals based on left ventricular wall motion |
US6885889B2 (en) * | 2003-02-28 | 2005-04-26 | Medtronic, Inc. | Method and apparatus for optimizing cardiac resynchronization therapy based on left ventricular acceleration |
US7092759B2 (en) * | 2003-07-30 | 2006-08-15 | Medtronic, Inc. | Method of optimizing cardiac resynchronization therapy using sensor signals of septal wall motion |
WO2005027785A2 (en) * | 2003-09-18 | 2005-03-31 | Advanced Bio Prosthetic Surfaces, Ltd. | Medical device having mems functionality and methods of making same |
US7248923B2 (en) * | 2003-11-06 | 2007-07-24 | Cardiac Pacemakers, Inc. | Dual-use sensor for rate responsive pacing and heart sound monitoring |
-
2005
- 2005-12-23 US US11/318,325 patent/US20060178586A1/en not_active Abandoned
-
2006
- 2006-02-03 US US11/347,623 patent/US20060178589A1/en not_active Abandoned
- 2006-02-07 WO PCT/US2006/004369 patent/WO2006086435A2/en active Application Filing
-
2008
- 2008-12-17 US US12/337,581 patent/US20090306736A1/en not_active Abandoned
-
2009
- 2009-03-02 US US12/396,420 patent/US8118751B2/en not_active Expired - Fee Related
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5031614A (en) * | 1986-09-12 | 1991-07-16 | Eckhard Alt | Pacemaker rate control using amplitude and frequency of activity signal |
US5454838A (en) * | 1992-07-27 | 1995-10-03 | Sorin Biomedica S.P.A. | Method and a device for monitoring heart function |
US5383473A (en) * | 1993-05-10 | 1995-01-24 | Pacesetter, Inc. | Rate-responsive implantable stimulation device having a miniature hybrid-mountable accelerometer-based sensor and method of fabrication |
US5425750A (en) * | 1993-07-14 | 1995-06-20 | Pacesetter, Inc. | Accelerometer-based multi-axis physical activity sensor for a rate-responsive pacemaker and method of fabrication |
US5628777A (en) * | 1993-07-14 | 1997-05-13 | Pacesetter, Inc. | Implantable leads incorporating cardiac wall acceleration sensors and method of fabrication |
US6077236A (en) * | 1994-06-07 | 2000-06-20 | Cunningham; David | Apparatus for monitoring cardiac contractility |
US5549650A (en) * | 1994-06-13 | 1996-08-27 | Pacesetter, Inc. | System and method for providing hemodynamically optimal pacing therapy |
US5715827A (en) * | 1994-09-02 | 1998-02-10 | Cardiometrics, Inc. | Ultra miniature pressure sensor and guide wire using the same and method |
US5540727A (en) * | 1994-11-15 | 1996-07-30 | Cardiac Pacemakers, Inc. | Method and apparatus to automatically optimize the pacing mode and pacing cycle parameters of a dual chamber pacemaker |
US6002963A (en) * | 1995-02-17 | 1999-12-14 | Pacesetter, Inc. | Multi-axial accelerometer-based sensor for an implantable medical device and method of measuring motion measurements therefor |
US5554177A (en) * | 1995-03-27 | 1996-09-10 | Medtronic, Inc. | Method and apparatus to optimize pacing based on intensity of acoustic signal |
US5792195A (en) * | 1996-12-16 | 1998-08-11 | Cardiac Pacemakers, Inc. | Acceleration sensed safe upper rate envelope for calculating the hemodynamic upper rate limit for a rate adaptive cardiac rhythm management device |
US6275724B1 (en) * | 1998-03-27 | 2001-08-14 | Intravascular Research Limited | Medical ultrasonic imaging |
US20020016615A1 (en) * | 1998-05-08 | 2002-02-07 | Dev Nagendu B. | Electrically induced vessel vasodilation |
US6542775B2 (en) * | 1998-05-08 | 2003-04-01 | Cardiac Pacemakers, Inc. | Cardiac pacing using adjustable atrio-ventricular delays |
US6650940B1 (en) * | 2000-02-02 | 2003-11-18 | Cardiac Pacemakers, Inc. | Accelerometer-based heart sound detection for autocapture |
US6643548B1 (en) * | 2000-04-06 | 2003-11-04 | Pacesetter, Inc. | Implantable cardiac stimulation device for monitoring heart sounds to detect progression and regression of heart disease and method thereof |
US6667725B1 (en) * | 2002-08-20 | 2003-12-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Radio frequency telemetry system for sensors and actuators |
US7270634B2 (en) * | 2003-03-27 | 2007-09-18 | Koninklijke Philips Electronics N.V. | Guidance of invasive medical devices by high resolution three dimensional ultrasonic imaging |
US7117035B2 (en) * | 2003-04-11 | 2006-10-03 | Cardiac Pacemakers, Inc. | Subcutaneous cardiac stimulation system with patient activity sensing |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8155756B2 (en) | 2007-02-16 | 2012-04-10 | Pacesetter, Inc. | Motion-based optimization for placement of cardiac stimulation electrodes |
US20090157136A1 (en) * | 2007-02-16 | 2009-06-18 | Pacesetter, Inc. | Motion-based optimization for placement of cardiac stimulation electrodes |
US8195292B2 (en) | 2007-02-16 | 2012-06-05 | Pacestter, Inc. | Cardiac resynchronization therapy optimization using parameter estimation from realtime electrode motion tracking |
US8346372B2 (en) | 2007-02-16 | 2013-01-01 | Pacesetter, Inc. | Motion-based optimization for placement of cardiac stimulation electrodes |
US20090254140A1 (en) * | 2007-02-16 | 2009-10-08 | Pacesetter, Inc. | Cardiac resynchronization therapy optimization using parameter estimation from realtime electrode motion tracking |
US9375160B2 (en) | 2007-05-16 | 2016-06-28 | Massachusetts Institute Of Technology | Systems and methods for model-based estimation of cardiac output and total peripheral resistance |
US20080287753A1 (en) * | 2007-05-16 | 2008-11-20 | Parlikar Tushar A | System and method for prediction and detection of circulatory shock |
US20080287812A1 (en) * | 2007-05-16 | 2008-11-20 | Parlikar Tushar A | Systems and Methods for Model-Based Estimation of Cardiac Output and Total Peripheral Resistance |
US9332911B2 (en) | 2007-05-16 | 2016-05-10 | Massachusetts Institute Of Technology | System and method for prediction and detection of circulatory shock |
US20080294057A1 (en) * | 2007-05-16 | 2008-11-27 | Parlikar Tushar A | Systems and methods for model-based estimation of cardiac ejection fraction, cardiac contractility, and ventricular end-diastolic volume |
US8282564B2 (en) | 2007-05-16 | 2012-10-09 | Massachusetts Institute Of Technology | Systems and methods for model-based estimation of cardiac output and total peripheral resistance |
WO2008144490A1 (en) * | 2007-05-16 | 2008-11-27 | Massachusetts Instutute Of Technology | Systems and methods for model-based estimation of cardiac ejection fraction, cardiac contractility, and ventricular end-diastolic volume |
US8235910B2 (en) | 2007-05-16 | 2012-08-07 | Parlikar Tushar A | Systems and methods for model-based estimation of cardiac ejection fraction, cardiac contractility, and ventricular end-diastolic volume |
US8262579B2 (en) | 2007-05-16 | 2012-09-11 | Massachusetts Institute Of Technology | System and method for prediction and detection of circulatory shock |
US20090036941A1 (en) * | 2007-07-31 | 2009-02-05 | Giorgio Corbucci | Cardiac resynchronization therapy for patients with right bundle branch block |
US8041424B2 (en) * | 2007-07-31 | 2011-10-18 | Medtronic, Inc. | Cardiac resynchronization therapy for patients with right bundle branch block |
US20090171413A1 (en) * | 2007-08-31 | 2009-07-02 | Marco Zenati | Implantable device, system including same, and method utilizing same |
WO2009029943A1 (en) * | 2007-08-31 | 2009-03-05 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Implantable device, system including same, and method utilizing same |
US8718764B2 (en) | 2008-09-16 | 2014-05-06 | Cardiac Pacemakers, Inc. | Cardiac function management integrating cardiac contractility modulation |
US8712520B2 (en) | 2008-09-16 | 2014-04-29 | Cardiac Pacemakers, Inc. | Cardiac function management integrating cardiac contractility modulation |
US20100069985A1 (en) * | 2008-09-16 | 2010-03-18 | Stahmann Jeffrey E | Cardiac function management integrating cardiac contractility modulation |
US8718761B2 (en) | 2008-09-16 | 2014-05-06 | Cardiac Pacemakers, Inc. | Cardiac function management integrating cardiac contractility modulation |
US20100069980A1 (en) * | 2008-09-16 | 2010-03-18 | Stahmann Jeffrey E | Cardiac function management integrating cardiac contractility modulation |
US8634910B2 (en) | 2008-09-16 | 2014-01-21 | Cardiac Pacemakers, Inc. | Cardiac function management integrating cardiac contractility modulation |
US8790264B2 (en) | 2010-05-27 | 2014-07-29 | Biomedical Acoustics Research Company | Vibro-acoustic detection of cardiac conditions |
US8972009B2 (en) | 2010-12-22 | 2015-03-03 | Pacesetter, Inc. | Systems and methods for determining optimal interventricular pacing delays based on electromechanical delays |
US20160051823A1 (en) * | 2014-08-22 | 2016-02-25 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker having a sensor with a lower power mode |
US9427589B2 (en) * | 2014-08-22 | 2016-08-30 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker having a sensor with a lower power mode |
US11660004B2 (en) * | 2016-10-27 | 2023-05-30 | City University Of Hong Kong | System, device and sensor for monitoring circulatory conditions and a method for manufacturing the same |
US10384058B2 (en) | 2017-06-16 | 2019-08-20 | Cardiaccs As | Methods and devices for securing a sensor at the heart |
Also Published As
Publication number | Publication date |
---|---|
WO2006086435A2 (en) | 2006-08-17 |
US20100049063A1 (en) | 2010-02-25 |
US8118751B2 (en) | 2012-02-21 |
WO2006086435A3 (en) | 2006-10-19 |
US20090306736A1 (en) | 2009-12-10 |
US20060178586A1 (en) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060178589A1 (en) | Accelerometer-based monitoring of the frequency dynamics of the isovolumic contraction phase and pathologic cardiac vibrations | |
US9265949B2 (en) | Method and apparatus for controlling cardiac therapy based on electromechanical timing | |
US8831705B2 (en) | Devices and method for accelerometer-based characterization of cardiac synchrony and dyssynchrony | |
JP4406720B2 (en) | Method and apparatus for optimizing cardiac resynchronization therapy based on left ventricular acceleration | |
US7092759B2 (en) | Method of optimizing cardiac resynchronization therapy using sensor signals of septal wall motion | |
US10765871B2 (en) | Implantable medical device with pressure sensor | |
US8150513B2 (en) | Method and apparatus for assessing left ventricular function and optimizing cardiac pacing intervals based on left ventricular wall motion | |
US8571642B2 (en) | Pre-ejection interval (PEI) monitoring devices, systems and methods | |
US20080288013A1 (en) | Pulmonary pressure monitoring | |
US8494631B2 (en) | System and method for profiling a patients hemodynamic response based on heart sounds | |
JP2008194496A (en) | Cardiac pacing using adjustable atrio-ventricular delays | |
EP1968697A1 (en) | Method and apparatus for improving cardiac efficiency based on myocardial oxygen consumption | |
US20210308467A1 (en) | Implantable medical device with pressure sensor | |
US20230329584A1 (en) | Body stability measurement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CARDIOSYNC, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DOBAK III, JOHN D.;REEL/FRAME:017544/0822 Effective date: 20060125 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |